SARS-CoV-2 Worldwide Replication Drives Rapid Rise and Selection of Mutations across the Viral Genome: A Time-Course Study Potential Challenge for Vaccines and Therapies

Stefanie Weber ¹ §, Christina M. Ramirez ² §, Barbara Weiser ³, Harold Burger ³, and Walter Doerfler ^{1,4*}

Institute for Clinical and Molecular Virology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, 91054 Erlangen, Germany ¹, Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA 90095-1772, USA ², Department of Medicine, University of California, Davis, Sacramento, CA 95817, USA ³, and Institute of Genetics, University of Cologne, 50674 Cologne ⁴, Germany

Running title: Mapping the Mutants of SARS-CoV-2 on the Viral Genome

*Address for correspondence

Walter Doerfler

Institute for Clinical and Molecular Virology
Friedrich-Alexander University (FAU) Erlangen-Nürnberg
Schlossgarten 4

D-91054 Erlangen, Germany

Tel.: +49-171-205-1587

E-mail: walter.doerfler@t-online.de

[§] These authors have contributed equally to this analysis

Significance and New Aspects of Study - Synopsis

- We examine the time course of emerging mutations in the SARS-CoV-2 genome that have rapidly been selected in the world's populations through the beginning of 2021. A study of the prevalence of viral mutations in the GISAID database in ten different countries United Kingdom, South Africa, Brazil, US, India, Russia, France, Spain, Germany, and China revealed widespread mutations along the genome.
- We previously identified about 10 hotspot mutations in the SARS-CoV-2 genome that became prevalent in many of the countries studied¹. Since the beginning of February, many new mutations arose in the ten countries (and worldwide). The preponderance of variants and mutations correlated with the increased spread of Covid-19.
- There was a temporal progression from about 10 predominant mutants shared by several countries up to the end of May 2020, followed by a consistent and rapid increase in the number of new mutations between June and December along with the emergence of variants of concern, first reported in December 2020.
- We examine the relative frequencies of mutations, along with variants of interest, in 10 countries up until January 20, 2021. Investigations on the pathogenic properties of individual SARS-CoV-2 mutations will be urgently needed to understand the kaleidoscopic patterns of worldwide Covid-19 outbreaks and symptoms. Monitoring the frequency and speed of mutant selection have direct relevance to diagnostic testing, vaccines and therapeutics.
- As an explanation for efficient viral mutagenesis, we hypothesize that the viral spike protein as documented facilitates viral entry via the cell's ACE receptor². This in turn interacts with the APOBEC polypeptide, an m-RNA editing function. The actually observed frequent C to U (T) transitions and other base exchanges are thus effected. Hence, as one of the earliest steps upon viral entry, active mutagenesis commences, since SARS-CoV-2 exploits one of the cell's defenses against viral infections.

Abstract

Scientists and the public were alarmed at the first large viral variant of SARS-CoV2 reported in December 2020. We have followed the time course of emerging viral mutants and variants during the SARS-CoV-2 pandemic in ten countries on four continents. We examined complete SARS-CoV-2 nucleotide sequences in GISAID, (Global Initiative of Sharing All Influenza Data) with sampling dates extending until January 20, 2021. These sequences originated from ten different countries: United Kingdom, South Africa, Brazil, USA, India, Russia, France, Spain, Germany, and China. Among the novel mutations, some previously reported mutations waned and some of them increased in prevalence over time. VUI2012/01 (B.1.1.7) and 501Y.V2 (B.1.351), the so-called UK and South Africa variants, respectively, and two variants from Brazil, 484K.V2, now called P.1 and P.2, increased in prevalence. Despite lockdowns, worldwide active replication in

genetically and socio-economically diverse populations facilitated selection of new mutations. The data on mutant and variant SARS-CoV-2 strains provided here comprise a global resource for easy access to the myriad mutations and variants detected to date globally. Rapidly evolving new variant and mutant strains might give rise to escape variants, capable of limiting the efficacy of vaccines, therapies, and diagnostic tests.

Keywords: SARS-CoV-2 mutation; UK variant B.1.1.7, VOC202012/01, (501Y.V2); South Africa variant B.1.351 variant; Spike mutations, mutational hotspots, time course of mutant emergence; Brazil variant, P.1, P.2; APOBEC-mediated editing

Introduction

Between December 2019 and January 28, 2021, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has expanded world-wide to 219 countries and territories; about 101.9 million people have been infected, and about 2.2 million (2.16 %) have lost their lives according to Johns Hopkins³.

In our laboratory, we have set out to follow the rapid rise of new mutations in the SARS-CoV-2 genome as Covid-19 cases soared worldwide. We identified mutation hotspots in different populations. Initially, we analyzed SARS-CoV-2 sequences that had been deposited in data bases between January and May/June of 2020. At least 10 prevalent sites of sequence mutations were observed and up to 80% of nucleotides at the mutated site were changed Several of these mutations led to non-synonymous amino acid changes in different open reading frames across the viral genome. These alterations in functional viral proteins were selected during active worldwide replication of SARS-CoV-2. We have now extended the time frame of mutant analyses to January 20, 2021, and found increased prevalence of mutations along the genome worldwide. We specifically examined mutations from the US, India, Brazil, Russia, the UK, France, Spain, Germany, South Africa and China that were deposited in the GISAID (Global Initiative of Sharing All Influenza Data) database⁴.

As of January 28, 2021, infection rates worldwide were extremely high, surpassing the levels seen at the peak in April 2020^3 . The uncontrolled spread may have led to a proliferation of mutants and variants, which we define as viruses with a specific set of mutations. The so-called UK variant, also known as B.1.1.7 or alternatively VOC202012/01, was first identified in England in September 2020, and reported on December 8^{th} as a rapidly spreading variant of concern that had 23 total mutations, 14 non-synonymous including 8 mutations in Spike, 6 synonymous, 3 deletions (**Table 1**) ⁵. Some of the mutations involve the gene for the Spike protein, which mediates binding, fusion, and entry of the virus into the host cell. One of these deletions, H69/V70 del (Δ H69/ Δ V70), has been reported to emerge during convalescent plasma treatment ^{6,7}. Another Spike mutation, N501Y, is of concern as it is suggested to interact with ACE2 and could reduce the effectiveness of neutralizing antibodies ⁸. This variant has been

associated with higher transmissibility^{9,10} and at least one confirmed case of reinfection¹¹ leading to lockdowns and travel bans in efforts to contain its spread. On December 23, 2020, the time of the lockdown, the variant was already found in Australia, Denmark and Italy. As of January 29, 2021, this variant is now reported in 54 countries according to GISAID (https://www.gisaid.org/hcov19-variants).

On December 18, 2020¹², another variant of concern, unrelated to the UK variant but also having the N501Y mutation, was announced in South Africa, and was dubbed 501Y.V2 or B.1.351¹³. This variant is characterized by 8 mutations in Spike including K417N, E484K and N501Y^{13,14} (Table 1). As of January 29, 2021 this variant has been reported in 24 countries and 5 continents.

Also rising independently, are 2 Brazil variants that are now called P.1 and P.2. P.1 has 17 unique amino acid changes, 3 deletions, 4 synonymous mutations and one 4 nucleotide insertion¹⁵ (Table 1). P.1 shares the 501Y and a deletion in ORF1ab with both the UK and the South Africa Variant. It is interesting to note that the N501Y mutation was not widely spread in Brazil before this variant was described while the E484K is more prevalent, although Brazil is not sequencing large numbers of samples. The E484K and the N501Y mutations are of particular concern in that they have been suggested to reduce neutralization by antibodies and increase the affinity for ACE2. P.1 and B.1.351 share both mutations N501Y and E484K (Table 1). P.1 has been associated with a case of documented reinfection¹⁶ and one case has been reported in the United States. P.2, unrelated to P.1, is characterized by the E484K mutation and has been implicated in two cases of reinfection^{17,18}.

These variants have caused concerns regarding efficacy of the vaccines. Recently Wu et al. described the efficacy of mRNA-1273 vaccine against many spike mutations tested both separately and in combination¹⁹. They show that sera from both vaccinated non-human primates and vaccinated humans are effective against the UK variant and various other spike mutations. They also found neutralization, albeit at lower levels, against the full South Africa variant B.1.135. It has been shown that the Pfizer BNT162b2 vaccine is effective against the N501Y mutant alone²⁰ as well as the UK variant B.1.117²¹, There have also been preliminary data from two other vaccine manufacturers showing efficacy against the South African variant. To illustrate the rise of mutations and variants over time, we list the number of variants and mutations deposited in GISAID worldwide across time (Figure 1). Table 2 lists the number of variant sequences deposited in GISIAD by country.

The rapid appearance of the variants across the world illustrates the importance of sequencing viral pathogens and tracking mutations. There is emerging evidence that these variants may alter transmissibility and have the potential to reduce the efficacy of existing COVID-19 vaccines. Sequencing SARS-CoV-2 is both a scientific and clinical imperative²². Because nucleic acid sequencing of SARS-CoV-2 samples is not part of routine clinical practice at this time, it is

necessary to institute programs to monitor sequence variation as a matter of course in order to detect mutations in the viral genome.

A consequence of the lack of routine viral sequencing is that it may contribute to selection bias. Sequences deposited to GISAID may not be representative of viral prevalence as different countries contribute different numbers of sequences. It is also possible that selection bias may be inherent, as different countries deposit sequences at different rates. Further, it was found that the Spike $\Delta H69/\Delta V70$ causes the so-called S-dropout, rendering the nucleic acid test (NAT) negative for Spike (S) and positive for nucleocapsid (N). As this is one of the mutations in B.1.1.7, it has been used as a screening tool for this variant²³. While useful for screening, this deletion might create selection bias because patients who were positive for SARS-CoV-2 with an S dropout may have their samples preferentially sequenced as the prevalence for the new variant is being assessed.

Rapid increases in the number and types of new SARS-CoV-2 mutations in the world population within a time span of weeks to months are a remarkable biologic event. The uncontrolled rapid replication of SARS-CoV-2 in an immunologically naïve world population during one year constituted a wake-up call of the need to sequence and track the evolution of novel pathogens as these mutations and variants have raised concerns regarding increased transmissibility, immune escape and the efficacy of vaccines and the validity of diagnostic tests.

Methods

We analyzed complete SARS-CoV-2 genome sequences with known dates of sampling that were downloaded from GISAID: (i) Only complete sequences were included. (ii) For a chosen time period, all complete sequences with a sampling date from each country were included. Sequences were binned according to sampling date. iii) Sequences by country were filtered by country using the GISAID interface²⁴. Nucleotide sequences from the UK, South Africa, Brazil, the US, India, Russia, France, Spain, Germany and China were compared to the reference genome of the SARS-CoV-2 isolate from Wuhan-Hu-1, NCBI Reference Sequence: NC_045512.2. The programs Vector NTI AdvanceTM 11 (InvitrogenTM), Tool Align X, or Snapgene (GSL Biotech), by using the algorithm MUSCLE (Multiple Sequence Comparison by Log-Expectation), for the alignment of sequences. Amino acid sequences were also analyzed with the program Snapgene. DNA sequence analyses of reverse-transcripts of an RNA genome will have to be considered with the possibility that errors may have been introduced at several steps. e.g., by preferred reading mistakes of the reverse transcriptase due to specific sequence or structural properties of SARS-CoV-2 RNA. We have tried to overcome this obvious complication by analyzing a large number of genomes. Percentages were calculated by dividing the number of sequences with the mutation that were sampled at that time and available in the database by the total number of complete sequences with a known sampling date. In addition to the determination of mutants for defined time spans in ten countries, the total number of individual mutations was also determined in all sequences deposited to GISAID up until January 20, 2021 by using GESS (Global Evaluation of SARS-COV-2/hCOV-19 Sequences²¹ as well as CoV-Glue²⁵ and PANGOLIN (Phylogenetic Assignment of Named Global Outbreak LINeages) https://github.com/hCoV -2019/pangolin)²⁶.

In the present study, somewhat arbitrarily, we set a 2% mark of mutations at a given nucleotide in the viral sequence as the cutoff for hotspot status and mutations recording in Tables 3 to 12. The SARS-CoV-2 RNA sequences investigated for mutant status had been deposited at time intervals of 2020 as follows:

Brazil: 02/25 to 08/15/2020; China-I: 12/23/2019 to 03/18/2020; China-II: 03/20 to 07/22/2020; France: April to 09/12/2020; Germany-I: February to 03/23/2020; Germany-II: February to 06/17/2020; Germany-III: 06/24 to 08/28/2020; Germany-IV 09/10 to 10/13; India: 01/27 to 05/27/2020 and 06/03 to 07/04/2020; Russia: 03/24 to 06/07/2020; South Africa: 09/01 to 12/07/2020; Spain: 06/01 to 09/20/2020; UK: 01/29 - 12/04/2020; US-I: 02/29 to 04/26/2020; US-II: 06/12 to 07/07/2020; US-III: 07/09 to 07/22/2020; US-IV 08/01 to 12/01. Some of the data had been reported previously in Table 1 of Weber et al. 2020¹, but were included here again for comparison. These data were designated with an asterisk.

Results

Time course of emerging mutations in ten different countries

We examined mutations in 383,570 complete sequences with known sampling dates in GISAID up until January 20, 2021. **Figure 1** shows the worldwide distribution of Spike mutations as well as other variants of interest over time from April 2020 to January 20, 2021. **Table 1** lists the signature mutations for the variants. **Table 2** shows the total number of each variant of interest (B.1.1.7 (the UK Variant), 501Y.V2 (the South African Variant) and 484K.V2 (B.1.1 lineage with S: E484K/D614G, V1176F N: A199S/R203K/G204R) deposited in GISAID by each country as of January 20, 2021.

Selection of novel mutations in humans was rapid and frequent in 2020. Among the novel mutations discovered in the current study, some were seen only in one country and others occurred in several different countries. We will present the identified mutations arising in the SARS-CoV-2 RNA country by country for the designated time periods (**Tables 3 to 12**). The data covering time course analyses of the appearance of mutations and their nature in most of the ten different countries are presented in Tables 3A to 12A, The corresponding B Tables summarize the total number of mutations in individual sequence position at a cut off of 2% preponderance for the time period 01/19/2020 to 01/20/2021, i.e. of the entire first Covid-19 year.

Mutation analyses in ten different countries

The following paragraphs document the mutational repertoire of SARS-CoV-2 in different regions of the world. The results are somewhat biased in that countries differed considerably in the number of sequences that had become available for inspection in the GISAID database

(www.gisaid.org)²⁴. We have emphasized the time course of appearance of novel mutations in SARS-CoV-2 isolates that had a history of vigorous replication in some of the most severely affected populations on the globe, such as UK, South Africa, Brazil, the US, India, Russia, France, Spain, Germany and China. The most recent update [January 30, 2021] of Covid-19 cases and fatalities in the ten countries, whose isolates were analyzed for mutations, are presented in Table 13.

(i) United Kingdom

For mutations arising in the UK, we have not followed the time course of emerging mutations during earlier periods of the pandemic. In a total of >71.000 viral isolates of SARS-CoV-2 genomes from around the world, that were deposited between 01/19/2020 and 01/20/2021, 4 of the prevalent mutations found worldwide, at positions 241, 3,037, 14,408 and 23,403, had reached almost 100% representation (**Table 3**). In a total of 70 sequence positions >2% deviations in comparison to the Wuhan reference were noted, > 50% were C to U (T) transitions (see also Tables 3 to 11B). Twelve novel mutations reached prevalence values between 15% and 49%, 7 of them around 49%. Several of these mutations were also found in other countries (Tables 4 to 12). High prevalence of new mutations correlated with active replication in countries of high Covid-19 incidence.

On December 8, 2020 Rambaut et al⁵ described a novel variant of SARS-CoV-2 that was circulating in England starting in October and increased in prevalence suggesting a possible increase in transmissibility^{9,10,22}. An analysis of its genome revealed 14 non-synonymous mutations and 3 deletions that comprised a few nucleotides. In the spike glycoprotein 6 of these mutations and 2 deletions were located, one of them N501Y due to an A23063T replacement. This particular variant is now considered a variant of concern VOC202012/01²². Current reports have described increased infectivity of this variant, whereas its pathogenicity is currently being assessed^{10,27}.

Recent reports suggest that Pfizer BNT162b2 vaccine is effective against the UK variant as well as the N501Y mutant alone^{20,21}. Wu et al show preliminary effectiveness for the Moderna vaccine (mRNA-1273)¹⁹ against the variant. Press reports from Novavax²⁸ are also suggestive of the effectiveness of NVX- CoV2373 against the UK variant. Table 2 lists mutations found in the GISAID database up until February 1, 2021 and also includes data on VOC202012/01 as well as B.1.351 and 484K.V2.

(ii) South Africa

We analyzed 95 SARS-CoV-2 sequences from viral isolates in South Africa that were deposited in the GISAID databank [**Table 4A**]; 28 mutations overall were found in those sequences. Four of the 7 prevalent mutations, known from isolates all over the world, had reached 100% representation in the SARS-CoV-2 sequences, except those at positions 1,059 (~10%), 25,563

(~10%), and 28,881 (~63%). There were 7 new mutations unique to the South African variant, four of which caused non-synonymous amino acid exchanges. Twelve of the novel mutations were shared with other countries, eight of these mutations led to amino acid exchanges, many of them to non-synonymous replacements. Twenty-five percent of the mutations affected the spike glycoprotein, a finding that should alert us to the capacity of the virus to respond to potential vaccines directed against the viral spikes. There was one each mutation that involved the viral endoRNAse and the RNA-dependent RNA polymerase.

For the entire year 2020 (January 19, 2020 to January 20, 2021), the four prevalent mutations at positions 241, 3,037, 14,408, and 23,403 were again [Table 4B] represented close to 100%, the mutation at 28,881/2/3 in the nucleocapsid phosphoprotein gene at about 70% [**Table 4B**]. There were 8 new mutations at >10% prevalence. In a total of 63 positions in the viral genome deviations from the Wuhan reference sequence were noted above the 2% cutoff.

Recently, the N501Y variant was detected in South Africa which also had two additional point mutations, K417 and E484K. Data about its possible increased infectivity and transmissibility were preliminary²⁹. Also in December 2020, another variant called 501Y.V2, B.1.351 also known South African variant is characterized by 8 lineage defining mutation with 3 in the receptor binding domains: K417N, E484K and N501Y. This variant also appeared to spread quickly in South Africa giving rise to travel bans from South Africa. It has been suggested that this variant is able to escape neutralization by donor plasma³⁰. Increased transmissibility has also been suggested²⁹. Furthermore, there is early evidence that the efficacy of multiple existing vaccines against the B.1.351 variant may be diminished^{19,28,31}. It will be important to continue to perform sequence analysis of viral strains and to correlate the evolution of mutants and variants with viral transmission and vaccine efficacy.

(iii) Brazil

In the nine SARS-CoV-2 mutations identified in a subset of about 100 published sequences available from Brazil in one time frame between 02/25 and 08/15 [**Table 5A**], five belonged to the worldwide prevalent hotspots at nucleotide numbers 241, 3,037, 14,408, 23,403, and 28,881. Two mutations at positions 12,053 and 25,088 were unique to the sequences from Brazil, and were noted in between 15.7 and 34.4 % of the analyzed sequences, respectively. Two of the novel shared mutations were also identified in sequences from France and Russia (27,299 and 29,148) at frequencies of about 40 %. The mutation at nucleotide position 28,881 was found in 71.6 % of the viral sequences studied. This mutation occurred in viral sequences from all countries investigated, except in those from China.

Of note, among the nine different new mutations observed in the SARS-CoV-2 isolates from Brazil, two were not observed in isolates from any of the eight other countries investigated. Possibly, they had recently emerged in the Brazilian population in which the virus had been replicating very actively, and the mutations had been selected under conditions of pandemic viral

abundance. The frequent $C \to T$ mutations amounted to 44.4% frequency in this selection. Note that the time analysis cut off occurred before the reported emergence of variant strains P.1 and P.2 were identified. We include the related 484K.V2 variant in Table 5B along with the number of individual mutations for all complete sequences with known sampling dates deposited to GISAID by January 20, 2021.

Impact on Coding Capacity: The two Brazil-unique mutations at positions 12,053 (viral replicase) and 25,088 (viral spike protein) led to leu to phe and val to phe synonymous replacements, respectively. The two novel shared mutations at positions 27,299 (ORF6 protein) and 29,148 (nucleocapsid phosphoprotein) both caused ile to thr replacements of a non-conservative nature.

Table 5B shows 27 individual mutations for the >1100 complete sequences with known sampling dates deposited to GISAID by January 20, 2021. The predominant mutations at positions 241, 3,037, 14,408, 23,403 showed frequencies at 99%. The mutation in the nucleocapsid phosphoprotein at position 28,881/2/3 presented with 93%, the highest frequency for this mutation among all 10 countries studied. As shown in Table 5A, in the time course study the nucleocapsid mutation reached a similarly high of 89%. C to U transitions in these samples reached only 29%. As of January 20, 5 cases of occurrence of the B.1.1.7 variant from the UK were reported.

(iv) USA

Table 6A lists mutations from a random subset of sequences selected in the US at 4 different time points. Some of the long-term prevalent mutations presented in the table under US-I and US-II were already included in a previous analysis as indicated by an asterisk¹. They were listed here again to facilitate comparisons to the wider spectrum of new mutations that arose in the US (US-III, US-IV) and in different countries in the course of a few weeks. In addition to the worldwide occurring prevalent mutations, at nucleotide (nt) numbers 241, 1,059, 3,037, 8,782, 14,408, 23,403, 25,563, 28,144, and 28,881, there were a total of 13 unique, i.e. not previously described mutations in our analyses of which nine were found exclusively in the US-III sample cohort at frequencies between 4 % and 29.3 % (Table 6A, unique). Except for three of these mutations, many attained their highest frequency of occurrence at the time point US-III. Two of the novel unique mutations in sequence positions 17,858 and 18,060 had disappeared in the US-III samples. Seventeen of the novel mutations were shared by other regions in the world, seven appeared in most or all ten countries investigated. We listed 13 mutations that had disappeared in the July samples of US-III, possibly they had proved not to be penetrating enough or were not sampled due to selection bias. As apparent in the table, five of the 15 new mutations among the US-II sequences deposited between June 12 and July 07 occurred at low frequencies (< 10%) exclusively in this collection of sequences, others, also at low frequencies, were also present in isolates from other countries as indicated. There were a number of novel shared mutations which were also represented in other countries- BR Brazil, CN China, FR France, DE Germany; IN India, RU Russia, ES Spain, ZA South Africa. The more recently selected SARS-CoV-2 mutations under US-III stemmed from the time period between July 09 and July 22, 2020. The comparison of June and July US-III sequences and their mutations to their counterparts from a month earlier (US-II) revealed the complex vitality of new mutants arising in a SARS-CoV-2 population that had been replicating during a most critical phase of the US pandemic during the summer of 2020. During the four months' period 08/01 to 12/01 (US-IV), another 117 SARS-CoV-2 sequences were added to Table 6A. Several of the predominant mutations reached 100% representation. Eight novel mutations, some unique, others shared, were listed at nucleotide positions 8,083, 10,139, 18,424, 21,304, 25,907, 28,472, 28,869, and 28,887; most of them reached >20% representation. At many nucleotide positions in the viral genome, the frequencies of the long-term predominant mutations increased over the entire time period between the last days of February to the end of July. This study has thus allowed us to witness the spread of mutations in the US population and at the same time the constant emergence of novel mutations and their increase in frequency with time.

Impact on Coding Capacities:

There is the idea that all mutations exist at a low level, but are detected when they are selected and proliferate. Of the 39 SARS-CoV-2 RNA sites mutated, 13 mutations, i.e. 42%, remained without effect on the encoded protein. In contrast, 18, i.e. 58%, exhibited changes in the genomes coding capacity [noted in red in Table 6A] which affected most of the virus-encoded proteins.. Most amino acid exchanges were non-synonymous and were likely responsible for functionally important alterations as judged from the type of amino acid replacements, e.g. pro to ser (nucleotide position 4,226) in nsp3; leu to phe (7,837), also in nsp3; tyr to cys (17,858) in the viral helicase; asp to gly (23,403) in the spike glycoprotein; arg-gly to lys-arg (28,881) in the nucleocapsid phosphoprotein and others. Among the additional eight mutations in the US-IV period, four led to non-synonymous amino acid exchanges in functionally important proteins as the 2'-O ribose-methyltransferase, the 5'-3' exonuclease, and the nucleocapsid phosphoprotein. The asp to gly exchange due to the mutation in position 23,403 that affected the viral spike glycoprotein, was described earlier¹⁸. The mutant grows to higher titers in cell cultures, reaches higher viral loads in the upper respiratory tract but does not lead to increased disease severity 18. The mutation has been reported to increase susceptibility to neutralization¹⁹. At this point, the functional consequences of most of the identified mutations for viral replication and/or pathogenicity need to be assessed. The SARS-Co-V-2 variant discovered in the UK in December 2020 will be discussed in part (iii) of the Conclusion section.

Analysis of mutation frequencies during short periods of time as compared to those observed over the entire year 2020: In addition, a total of 52,934 SARS-CoV-2 sequences from the US in GISAID was analyzed for the presence of mutations as compared to the original Wuhan sequence (**Table 6B**) over the entire year 2020. A total of 42 sequence positions showed >2% deviations from the reference sequence; 21 (50%) were C to U (T) transitions. Similarly high C to U preferences in sequence exchanges were observed in isolates from some of the other 9 countries that were analyzed. In the Conclusion section of this work, a presumptive editing function

(APOBEC) is discussed to account for the prevalence of C to U transitions in all these viral genomes. SARS-CoV-2 represents itself as a highly adaptable virus that optimally utilizes its and the host cell's capacities to generated mutations and has them efficiently selected under a wide range of conditions in human populations.

As of January 20, 2021, a total of 81 isolates of the UK variant B.1.1.7 was reported in the US which is probably a gross underestimate, by January 22 this variant had reached 12 US states. Worldwide, the occurrence of SARS-CoV-2 mutations and variants is changing daily as expected at the height of this pandemic.

(v) India

During the periods of sequence analyses between January 27, 2020 to May 27, 2020 (IN-I) and June 03, 2020 to July 04, 2020 (IN-II) the prevalent hotspot mutations at sequence positions 241, 3,037, 14,408, 23,403, and 25,563 had reached values of representation approaching 100 %, except at position 25,563 which amounted to 52% of sequences [Table 7A]. New mutations emerged during these time periods. A set of nine novel mutations, unique to the Indian population, were observed, i.e. 39.1% out of a total of 23 mutations in all sub-samples from India. These unique mutations were located in genome positions which were completely different from the newly arising SARS-CoV-2 mutations in the US or in any other population investigated in our study [Table 7A]. A total of seven of these novel mutations originated or increased in frequency in the late IN-II time period, whereas two of the mutations could no longer be detected during that same period. An additional nine newly arising mutations were shared with those in countries as indicated, some of which reached a frequency of up to 50%. Among all mutations from the Indian samples, $C \to T$ transitions held the majority of 15/23, i.e. 65.2%. We note that 18 out of 23 (78.3%) mutations in the SARS-CoV-2 isolates from our sub-samples from India were novel. About 7/9 of the India-unique mutations appeared de novo or increased in frequency within a time period of a few weeks of very active replication of the virus in the Indian population. New mutations are not only perpetually arising during the present stage of a nearly uncontrolled Covid-19 pandemic, but are also capable of becoming selected in Indian population. **Table 7B** lists 46 individual mutations for >3270 complete sequences with known sampling dates deposited to GISAID by January 20, 2021. The prevalent mutations at positions 241, 3,037, 14,408, and 23,403 (Tables 3 – 12) were represented at about 86%, at position 28,881 at 44%. In total 46 positions showed mutations at frequency levels >2%, ten of them >10%. The frequency of C to U transitions among all mutations in the samples from India was 50%.

Impact on Coding Capacity: The change in coding capacity of the long-term prevalent mutations in positions 241, 3,037, 14,408, and 23,403 was described for the US samples. Among the nine India-unique mutations, the following four led to functionally significant amino acid exchanges: Position 2,292 (nsp2) gln – pro; 18,568 (3'–5'-exonuclease) leu – phe; 19,154 (3'–5'-exonuclease) thr – ile; and 28,311 (nucleocapsid phosphoprotein) ser – leu. Among the nine additional mutations, which were shared by one or several countries, only the following four led to amino acid exchanges: 6,312 (nsp3) thr – lys; 11,083 (nsp6) leu/tyr – phe; 21,724 (spike

protein) leu-phe – phe-phe; 28,854 (nucleocapsid phosphoprotein) ser – leu (Table 7A). Again, many of the new SARS-CoV-2 mutations were responsible for functionally important non-synonymous amino acid exchanges in the corresponding protein.

(vi) Russia

Among the RU-I subsample of 226 SARS-CoV-2 RNA sequences analyzed between 03/24 and 06/07/2020 in the isolates from Russia, there were ten mutations of which six belonged to the previously described long-term prevalent mutations at positions 241, 3,037, 14,408, 23,403, 25,563, and 28,881 **[Table 8A]**. The latter mutation in position 28,881 at a frequency of representation of 76.1% stood out in that it was not a point mutation but involved a three nucleotide exchange creating a highly basic domain in the 3' terminal region of the SARS-CoV-2 nucleocapsid phosphoprotein as reported earlier¹. The 28,881 mutation in the Russian sequences had reached one of the highest frequency at 88%. The four new mutations were located at sequence positions 3,140 (CC \rightarrow TC, with a pro to asn-leu exchange in the amino acid sequence of nsp3), 20,268 (AG \rightarrow GG, without change in amino acid composition in the endo RNase), 26,750 (CA \rightarrow TA, without effect on the membrane glycoprotein), and at 27,415 (GC \rightarrow TC, and an ala to ser change in the ORF6 protein).

Table 8B presents similar results of analyses on about 1,330 sequences collected during one year between 01/19/2020 - 01/20/2021. Again the prevalent mutations had reached close to 100% frequency, the nucleocapsid phosphoprotein about 90%. New mutations were not apparent. C to U transitions stood at 38%.

As of January 20, the detection of any of the new SARS-CoV-2 variants was not reported in Russia.

(vii) France

Mutation frequencies were determined between 04 and 09/12, 2020 (116 SARS-CoV-2 sequences). In the sequences a total of 27 mutations were documented. Among them, seven of the previously described long-term prevalent mutations were identified at frequencies as follows: Nucleotide position 241 (100%), 1,059 (13.8%), 3,037 (99.1%), 14,408 (98.3%), 23,403 (100%), 25,563 (49.1%), 28,881 (14.7%). There were 20 new mutations at frequencies between 10 and 20% that were not described previously¹. C - U transitions reached 37%. [**Table 9A**]. Of interest, none of the new mutations was unique to France in the 116 sequences displayed in Table 9A. Instead, a large percentage of the mutations were shared with Germany and Spain, both neighboring countries. Most novel mutations occurred between 10% and 20% [Table 8A] at frequencies between 10 and 20%. C to U transitions were found in 46% of sequences. Among the novel mutations, 20 occurred at >10, many of them >20% frequencies.

Table 9B lists mutational frequency in sequences deposited up until January 20, 2021, including data on variants of interest and of concern. There are scant data on the occurrence of variants [Table 2], the UK variant B.1.1.7 was counted 20 times, the South African one 5 times. As

complete sequence analyses on Covid-19 isolates are progressing rapidly, new data on the emergence of new variants can be expected.

Impact on Coding Capacity: Among these 20 not-previously described novel mutations, eight did not affect the coding capacity of the relevant viral proteins. Most of the 12 coding-relevant mutations led to amino acid exchanges that were non-synonymous: nsp2, 3, 4, RNA-dependent RNA polymerase, the helicase, the endoRNAse, the spike glycoprotein, and the nucleocapsid phosphoprotein [Table 9A, B].

(viii) Spain

In the Spanish isolates from the period between 06/01 and 09/20/2020, we analyzed 135 sequences and observed 20 mutations [**Table 10A**]. Of these, four, the long-term prevalent ones, had been described earlier in positions 241, 3,037, 14,408, and 28,881. Except for the latter one at 10.4% frequency, the three former came close to 100% occurrence. Of the 16 new mutations, six occurred in Spanish isolates exclusively (termed unique), namely in positions 5,572 (GT \rightarrow TT, frequency 8.1%, changing the amino acid sequence met to ile in nsp3), 5,784 (CT \rightarrow TT, frequency 9.6%, thr to ile in nsp3), 25,062 (GT \rightarrow TT, frequency 13.3%, amino acid change gly to val in the spike glycoprotein), 27,982 (CA \rightarrow TA, frequency 9.6%, changing the sequence from pro to leu in the ORF8 protein), 28,657 (CG \rightarrow TG, at frequency of 14.1%, without affecting the nucleocapsid phosphoprotein), and 28,932 (CT \rightarrow TT at frequency of 65.9% and altering the amino acid composition in this position in the nucleocapsid phosphoprotein from ala to val). The remaining 10 novel shared mutants were also found in isolates from other countries and were located in positions as shown in previous tables. With the exception of a point mutation at position 25,049 in the spike glycoprotein and an ensuing amino acid exchange from asp to tyr, none of the other nine mutations in the shared category led to an amino acid exchange.

We also note that in the Spanish collection of SARS-CoV-2 mutations, there were four in the spike glycoprotein, all different from the well-known position 23,403. Two of these new spike mutations led to non-synonymous amino acid exchanges in the spike glycoprotein: In position 25,049 asp to tyr, and in 25,062 gly to val [Table 10A]. Such mutations might become relevant when evaluating the efficacy of a solely spike-directed SARS-CoV-2 vaccine. As a note of caution, one should not rule out functional consequences of nominally silent mutations for SARS-CoV-2 competence, since they might affect the secondary structure of the viral RNA with sequelae in replication and relevant interactions of the viral genome with viral and/or cellular proteins.

It is interesting to note that although the latest Spanish collection of SARS-CoV-2 mutations contains four mutations in the spike glycoprotein, in earlier time points, the D614G mutation at position 23,403, the site of a prevalent mutation^{1,32} was not present [Table 10A]. In **Table 10B**, describing mutant frequencies between 01/19/2020 and 01/20/2021, the 23,403 mutant was present at about 80%, whereas in France and England prevalence was >96%. Moreover, for the 01/2020 to 01/2021 period, mutations in 38 sequences lay above the 2% cut off. The predominant

mutations reached values around 80% representation. C to T transitions were at 42%. Among the novel mutations 17 showed prevalence of >10%, 8 of them of >20%.

(ix) Germany

During the course of the pandemic, we tabulated the occurrence of SARS-CoV-2 mutants which arose between February to 03/23 (DE-I)¹, February to 06/17 (DE-II), 06/24 to 08/28 (DE-III), the latter isolates with only 17 sequences available for analyses, and 09/10 to 10/13 (DE-IV) with 70 sequences. Apart from the prevalent mutations, there were relatively few mutations exceeding 10% representation in the time frame of DE-II. Among the total of 33 mutations in the SARS-CoV-2 RNA sequence [Table 11A], seven belonged to the previously described collection of long-term prevalent sequences – at positions 241, 1,059, 3,037, 14,408, 23,403, 25,563, 28,881 with coding frame alterations as outlined in previous Tables. In the DE-III sample, four of these long-term prevalent mutations had reached 100% representation, two had disappeared, and the mutation at 28,881 had remained at about 53%. Six mutations could be detected exclusively in the DE-III samples from Germany, in positions 3,602 (CA \rightarrow TA), 6,941 (CT \rightarrow TT), 21,855 $(CT \rightarrow TT)$, 25,505 (AA \rightarrow GA), 25,906 (GG \rightarrow CG), 28,869 (CA \rightarrow TA), all of them at 29% of representation. There were mutations in six positions which had been observed also in isolates from other countries, as indicated, and all of them showed modest frequencies. It is interesting to note that 52% of the mutations detected in sequences from France were shared with Germany, but only 16% of the mutations identified from Germany were shared with those from France [Table 9A]. During the time interval of about a month, 09/10 to 10/13 (DE-IV), that immediately preceded a marked rise in Covid-19 cases in Germany, 23 new mutations were identified 6 of which reached a prevalence of >20% and 7 of >10% in the SARS-CoV-2 sequences studied. During the same period, 4 of the prevalent mutations were represented in 100% of sequences, one, at 28,881 of 54%.

Table 11B lists the total number of mutations and variants up until January 20, 2021 from GISAID complete sequences with 52 entries at >2% incidence. The prevalent mutations reach about 86% occurrence. Only at three sites, mutations were found at >10%. C to U transitions were recorded in 46% of the studied sites.

Impact on Coding Capacity: With the exception of the point mutation at 6,941 which was synonymous, the five other mutations were non-synonymous: 3,602 his to tyr (nsp3); 21,855 ser to phe (nsp3); 25,505 glu to arg (ORF3a protein); 25,906 gly to arg (ORF3a protein); 28,869 pro to leu (nucleocapsid phosphoprotein).

(x) China

In late December of 2020, the first cases of Covid-19 emerged in Wuhan, Hubei Province in China, reportedly among workers and customers of the Huanan Seafood Market. The Chinese authorities eventually reacted with a very strict shutdown in Hubei Province, the epicenter of Covid-19, to limit the spread of the new disease. At present, most new cases of Covid-19 are

reportedly being registered in Shanghai and a few additional places. The analyses of SARS-CoV-2 mutants up to March 18, 2020 (CN-I) revealed point mutations in only two genome positions, 8,782 (CC \rightarrow TC, without amino acid exchanges) and 28,144 (TA \rightarrow CA causing a leu to ser exchange in ORF8 protein), both at frequencies of 29.3% [Table 12A]. An extension of our mutant research among a relatively limited number of published sequences to the period from 03/20 to 06/22, 2020 (CN-II) revealed mutations in five of the long-term prevalently affected sequence positions: 241 (CG \rightarrow TG at a frequency of 69.7% without coding changes), 3,037 (CT \rightarrow TT, at a frequency of 69.7%, without coding changes), 14,408 (CT \rightarrow TT at a frequency of 57.6% and a codon change pro to leu in the gene for the RNA-dependent RNA polymerase), 23,403 (AT \rightarrow GT at a frequency of 66.7% and an asp to gly exchange in the spike glycoprotein), and at 28,881 (GGG → AAC at a frequency of 33.3% and the codon exchange arg-gly to lys-arg, reported previously). Remarkably, the novel shared point mutations in positions 8,782 and 28,144 had disappeared at the later time point [Table 21]. These latter mutations may have been introduced to China by visitors or business travelers, and then died out because they did not confer a strong evolutionary advantage or due to not enough sequencing. The total counts of mutations up until January 20th are presented in Table 12B.

Conclusions and Problems

(i) SARS-CoV-2 genetics will require in-depth analyses

It has been the intent of this project to follow the genetic evolution of SARS-CoV-2 after the virus transgressed a host barrier and during the ensuing major pandemic in the human population. The virus has shown great replicative and mutagenic potential and appeared in the large human population of 7.8 billion that lacked previous encounters with SARS-CoV-2. In this context, the primary question was not to understand viral mutagenesis in general in its biochemical or genetic details, but to identify mutants that have potential to become prevalent with possible fitness advantages. Which mutants and variants would have the capability to persist and multiply in the course of rapid spread of SARS-CoV-2 within the human population? It will be a continuing long-term challenge to pursue the outcome and time course of a competition in that 29,903 nucleotides in the viral genome were pitted against about 3 billion in the human genome. The SARS-CoV-2 has a repertoire of mutable sites in a stretch of 29,903 nucleotides that cannot only be varied by introducing point mutations but be extended by an almost inexhaustible combination of multiple mutations in the same genome, by deletions and insertions. Before the viral dominance in the human population began, SARS-CoV-2 had already made a major leap, its transition from an animal to the novel human host, an undocumented step in its own right in which mutagenesis and selection must have played a major role. Thus, the impact of ethnic and socio-economic differences in the human population will have to be considered as important factors. In a summary of all mutation analyses we have compared the number and types of mutations to the extent of the Covid-19 pandemic in ten different countries that currently report high numbers of cases and fatalities [Table 13].

Of course, this summary offers only a broad temporal correlation of mutant data and extent of the pandemic in individual countries. High current incidence of Covid-19 is paralleled by high numbers of new mutations and variants, although this relationship was not observed in Brazil or Russia. In anticipation, it will be a further challenge to evaluate the real-world success of the numerous Covid-19 vaccination programs.

(ii) Replication and selection

Rapid worldwide replication of SARS-CoV-2 in heterogeneous populations has been paralleled by the rise of novel mutations. In this report, we have studied mutations in SARS-CoV-2 RNA sequences isolated in the UK, South Africa, Brazil, the US, India, Russia, France, Spain, Germany and China that have become available in the GISAID database during a one-year period between January 19, 2020 and January 20, 2021. We have examined the rise of novel mutations both using sequence subsets segregated by date and also overall in a large cross-section. It seems that towards the end of the year, more mutations in combination were found and propagated rapidly despite lockdowns and other efforts to contain the spread, perhaps owing to potential increased transmissibility. The current data are compatible with the interpretation that rapid regional expansion and efficient viral replication in human populations of very different genetic and socio-economic backgrounds further the selection of new mutations in the viral RNA genome. Differences in defense mechanisms operative in various populations infected by SARS-CoV-2 and/or the various therapeutic measures employed in fighting the infection might also have influenced the selection of new mutants. It is uncertain whether there was regions-specific selection of specific mutations or whether other factors might have furthered differences in unique versus shared novel mutations.

Figure 1 and Table 1 show the number of novel variants in each country as of January 20, 2021. The speed by which the virus traveled even during lockdowns emphasizes the difficulty in suppressing transmission of highly contagious respiratory viruses. The new variants have not been associated with increased pathogenesis although more research needs to be done. The preliminary finding of increased transmissibility of the B.1.1.7 and B.135 variant hinder efforts to contain the virus^{5,9,10,13,22,27,29,30}. The vaccines are expected to work against the novel variants, although with some at reduced efficacy^{19,20,28,31}, but caution is urged to watch viral evolution.

(iii) Rise of novel mutations and variants with new properties – A hypothesis

After initially demonstrating the prevalence of about 10 mutants in at least 10 different countries, SARS-COV-2 evolved to display new point mutations worldwide that were selected among affected populations in a time period of weeks [Tables 3 A, B to 12 A, B]. In **Table 13**, column 5, the number of new point mutations in some of the countries analyzed ranged between 16 and 38. As a consequence of highly efficient sequencing programs in the UK [UK Consort], previously not recognized variants started to appear in late 2020 and are currently spreading worldwide

(Figure 1,Table 2). The impact of these variants on potential increases of the already existing pathogenicity cannot be UK, South Africa, Brazil, the US, India, Russia, France, Spain, Germany and China assessed at present.

We posit the following hypothesis: SARS-CoV-2 uses the ACE2 (angiotensin-converting enzyme 2) receptor for its entry into human cells². It remains to be determined how the interaction of ACE2 receptor with the spike protein of SARS-CoV-2 affects the location and activity of APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide). This class of m-RNA editing functions causes deamination of cytosine to uracil³³. The high frequency of C to T (U) transitions among SARS-CoV-2 mutants-- among them, 40.7% (France), 59% (US) to 69.9% (India) – as examples - were C to U (T) transitions (see also Tables 4B to 12B) [see Table 13] – up to >88% in the UK samples - might be linked to an m-RNA-editing mechanism^{1,34,35}. Moreover, the high incidence of C to T (U) transitions renders research on the occurrence of methyl-cytosine bases in SARS-CoV-2 RNA a project of considerable importance. In this context, the introduction of 14 point mutations and 3 small deletions in the genome of the B.1.1.7 suggests m-RNA editing as a plausible model. The rapid generation of SARS-CoV-2 point mutations and the sudden rise of ubiquitous and efficiently selected SARS-CoV-2 variants also supports the m-RNA editing mechanism as an attractive hypothesis. The editing function has been interpreted as a cellular defense against intruding viral genomes, and SARS-CoV-2 exploits exactly this mechanism to further its mutagenic potential.

(iv) Will the constant selection of new mutants impinge upon the success of therapeutic or vaccination strategies?

There are multiple sources of vaccines against Covid-19 available now or at various stages of including those from Pfizer/BioNTec; AstraZeneca/Oxford University; Moderna/US National Institutes of Health; Johnson and Johnson Novavax; Curevac/Bayer and firms in Russia, China, India, and many more. It is impossible to assess the vaccines' overall long-term efficacy against SARS-CoV-2 infections at this time. Vaccines available now have demonstrated a high level of clinical efficacy. There are also, however, preliminary data suggesting that evolution of viral variants may have diminished efficacy of several vaccines against one of the new SARS-CoV-2 variants 19,28,31,36. The emergence of novel mutants of SARS-CoV-2 in short temporal succession and their difficult-to-assess impact on pathogenicity in vivo further complicate predictions about future vaccine efficacy at this time. For example, some of the early laboratory assessments of efficacy versus the new variants have focused on neutralization by sera from immunized individuals; the clinical efficacy of vaccines, however, is likely to benefit from cell-mediated immunity as well. Furthermore, sophisticated and specific plans are already in place to alter the Covid-19 vaccines to compensate for possible escape mutants. SARS-CoV-2 is a new and evolving pathogen. Effective vaccines have been developed within one year of the identification of the pathogen, a remarkably short time. Ingenuity and basic research are likely to offer solutions to help control the spread of SARS-CoV-2 and future emerging viruses.

Note added during submission

Domingo and Perales [J. Virol. 2021, doi: 10.1128/JVI.02437-20.] point out that the time for Covid-19 vaccination should be at low incidence of disease, in order to avoid selection of SARS-CoV-2 escape mutants.

(v) "Conceptual bridge between natural language and viral evolution"

With this conceptual bridge, Hie et al. studied viral escape mechanisms to circumvent cellular defenses by adapting machine learning algorithms that had been developed to analyze human languages³⁷. The viral mutation seeks to escape by looking different to the immune system akin to word changes keeping the grammar of a sentence while altering its meaning. With that seemingly remote approach, the authors hope to predict viral structures that will be able to escape immunological defenses. This idea has been applied to influenza hemagglutinin, HIV-1 envelope glycoprotein and SARS-CoV-2 spike glycoprotein. Will an intellectual *spiel* from linguistics can actually help solve a complex biological problem remains to be seen and a subject for future work.

Acknowledgments

We acknowledge and are very grateful to the GISAID Initiative and for the hard work and openscience of the individual research labs and public health agencies that have made their genome data accessible on GISAID, on which this research is based.

This research was supported by the Dr. Robert Pfleger Stiftung in Bamberg, Germany [5.12.2018]. W.D. is indebted to the Institute for Clinical and Molecular Virology of FAU in Erlangen, Germany for their continued hospitality extended to the Epigenetics Group.

Competing interests

The authors declare no competing interests.

Author contributions

S.W. carried out all work involving sequence selection and formal analyses, was involved in the conceptualization of the project and in the analysis and interpretation of data. C.R. performed the analysis on the large sequence database and variants of interest/concern using GISAIS, GESS, CoV-Glue and other computational tools, statistical analyses, interpretation of the data, and writing of the manuscript. B.W. and H.B. contributed to the analysis and interpretation of the data. B.W. contributed to writing the manuscript. W.D. initiated the project, was involved in the conceptualization of the project, in the analysis and interpretation of data and wrote the manuscript with C.R.'s and B.W.'s contributions.

References:

- 1. Weber S, Ramirez C, Doerfler W. Signal hotspot mutations in SARS-CoV-2 genomes evolve as the virus spreads and actively replicates in different parts of the world. Virus Research 2020;289.
- 2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;182:812-27.
- 3. Dong E, Du H, Garner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Inf Dis 2020;20:533-4.
- 4. Elbe S, Buckland-Merritt G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges 2017;1:33-46.
- 5. Rambaut A, Loman N, Pybus O. Preliminary genomic characterisation of an emergentSars-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virologicalorg 2020.
- 6. Kemp S, Collier D, Datir R, al. e. Neutralizing antibodies in Spike mediated SARS-CoV-2 adaption. MedRxiv 2020.
- 7. Kemp S, Datir R, Collier D. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion $\Delta H69/\Delta V70$ MedRxiv 2020.
- 8. Yi C, Sun X, Ye J, al e. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 2020;17:621-30.
- 9. NERVTAG. New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG meeting on SARS-CoV-2 variant under investigation VUI-202012/01. 2020.
- 10. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. MedRxiv 2021;2020.12.30.20249034.
- 11. Harrington D, Kele B, Pereira S, Coutyo-Parada X, Riddell A, al e. Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01. Clinical Infectious Diseases 2021;ciab014.
- 12. WHO. SARS CoV-2 Variants. In: News DO, ed.2020.
- 13. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv 2020.
- 14. Pond S, Wilkison E, Weaver S, James S, H T, al e. A preliminary selection analysis of the South African V501.V2 SAR-CoV-2 clade. virologicalorg 2020.
- 15. Faria N, Claro I, Candido D, Franco L, al e. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. virologicalorg 2021.
- 16. Naveca F, da Costa C, Nascimento V, Souza V, Corado A, al e. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil. Virologicalorg 2021.
- 17. Nonaka C, Franco M, Graf T, Mendes A, de Aguiar R, al e. Genomic evidence of a SARS-CoV-2 reinfection case with E484K spike mutation in Brazil. preprintsorg 2021.
- 18. Resende P, Bezerra J, de Vasconcelos R, Arantes I, Appolinario L, al e. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. virologicalorg 2021.
- 19. Wu K, Werner A, Molivs J, al e. mRNA-1273 vaccine induces neutralizing antibodies against spike mutations from global SARS-CoV-2 variants. . bioRxiv 2021.
- 20. Xie X, Zou J, Fnter-Garfias, al e. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicted sera. bioRxiv 2021.

- 21. Collier DA, Meng B, Ferreira I, Datir R. Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2. . MedRxiv 2021.
- 22. Consortium CUC-GU. COG-UK report on SARS-CoV-2 spike mutations of interest in the UK2021 01/15/2021.
- 23. Washington N, White S, Schiabor Barrett K, al e. S gene dropout patterns in SARS-CoV-2 tests suggest repread of the H69/V70del mutation in the US. medRxiv 2020.
- 24. Shu Y, J M. GISAID: Global initiative on sharing all influenza data from vision to reality. . EuroSurveillance 2017;22.
- 25. Singer J, Gifford R, Cotten M, Robertson D. CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation. Preprint 2020;2020060225.
- 26. Rambaut A, Holmes E, O'Toole A, al e. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 2020;5:1403-7.
- 27. Santos J, GA P. The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation. biorxiv 2021.
- 28. Novavax. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. 2021.
- 29. Cheng M, Krieger J, Kaynak B, Arditi M, Bahar I. Impact of South African 501.V2 variant on SARS-CoV-2 spike infectivity and neutralization: A structure-based computational assessment. bioRxiv 2021.
- 30. Wibner C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, al e. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv 2021.
- 31. Johnson J. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. 2021.
- 32. Korber B, Fisher W, Gnankaran S, Yoon H, Theiler J, al e. Tracking changes in SARS-CoV-2 spike: evidence that D614G

increases infectivity of the COVID-19 virus

- . Cell Mol Immunol 2020;182:812-7.
- 33. Anant S, Davidson N. Molecular mechanisms of apolipoprotein B mRNA editing. Curr Opin Lipidol 2001;12:159-65.
- 34. Di Giorgio S, Martignano F, Torcia MG, Mattiuz G, Conticello SG. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv 2020;17.
- 35. Simmonds P. Rampant C→U hypermutation in the genomes of SARS-CoV-2 and other coronaviruses: Causes and consequences for their short- and long-term evolutionary trajectories. mSphere 2020.
- 36. Xie X, Liu Y, J L, Zhang X, Zou J, al e. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. biorxiv 2021.
- 37. B H, Zhong E, Berger B, Bryson B. Learning the language of viral evolution and escape. Science 2021;371.

Legends to Figures and Tables

Figure 1:

Global Mutations/Variants over time from April 1, 2020 to January 20, 2021 for all countries. Complete sequences with known dates of accession were downloaded from GISAID on January 20, 2021. Months were assessed from the submission data and subsetted on those with reported sampling dates.

Table 1:

Mutations associated with variants B.1.1.7 (UK), B.1.135 (South Africa), P.1 (Brazil) and P.2 (Brazil).

Table 2

Variants of SARS-CoV-2 by country as of January 20, 2021. Currently, new variants are being detected and characterized in rapid succession. This Table could be outdated by the time of publication. For updating of data consult GISAID²⁴.

Table 3 – United Kingdom

Details of the mutant analyses of 7,144 SARS-CoV-2 isolates for deviations from the Wuhan reference sequence. These sequences were deposited in the GISAID initiative between 01/19/2020 and 01/20/2021. For design of Tables see legend to Table 4.

Table 4 – South Africa

The Table presents characteristics of SARS-CoV-2 mutants from South African isolates. For Table design, see legend to Table 6.

Table 5 - Brazil

The Table presents characteristics of SARS-CoV-2 mutants from isolates collected in the Brazilian population. For Table design, see legend to Table 6.

Table 6 - USA

The general design of this Table is similar to Tables 3 to 5, and 7 to 12, with minor modifications. **Part A:** From the overall analyses of the entire SARS-CoV-2 RNA sequence from 112 (US-I), 97 (US-II), 99 (US-III), and 117 (US-IV) randomly chosen isolates, the mutated nucleotides (nt) – as compared to the original Wuhan sequence – were tabulated. The actual time periods of mutant selections for the US-I to US-IV samples were indicated. Mutations previously designated as "signal hotspots" [Weber et al, 2020, i.e. 241 - 1,059 - 1,440 - 2,891 - 3,037 - 8,782 - 14,408 - 23,403 - 25,563 - 28,144 - 28,881] were now designated "prevalent". The * in the US-I and US-II columns designates previous publication in [Weber et al. 2020^{1}]. The actual nucleotide changes were indicated in the third column, the most frequent being $C \rightarrow T$ (here 59 %), as reported previously [Simmonds et al. 2020^{35} ; Weber et al. 2020^{1}]. Locations of mutations on the viral genome and amino acid exchanges as consequences of individual mutations were tabulated in columns 2 and 3, respectively. In columns 4 to 7, the actual frequencies of mutations at the four time intervals (US-1 to US-IV) were listed. The following designations for individual countries were chosen: BR for Brazil, CN for China, DE for Germany, FR for France, IN for India, RU for Russia, ES for Spain, ZA for South Africa, UK for United Kingdom, and US for USA.

The GGG \rightarrow AAC is a non-point mutation in nucleotide position 28,881 that generated a highly basic amino acid sequence in the SARS-CoV-2 nucleocapsid phosphor-protein. We have speculated that this mutation might have originated from a recombination event between different viral RNA molecules [Weber et al, 2020^1]

Part B: A total of 5,710 SARS-CoV-2 from the GISAID source was analyzed. Deviations from the Wuhan reference sequence of >2% incidence were found at 42 sites in the sequence. Further details were described in the text.


Table 7 – India, Table 8 – Russia, Table 9 – France, Table 10 – Spain, Table 11 – Germany, Table 12 - China

The general design of these Tables follows the outline described in detail in the legend to Table 6 (USA). The number of sequences investigated for SARS-CoV-2 mutations was detailed in Tables for individual countries.

Table 13 (Survey)

The rise of new SARS-CoV-2 mutations in many countries was juxtaposed to the high Covid-19 incidence values around the world. World incidence of Covid-19, as of January 30, 2021 in 219 Countries was Covid-19 cases – 102,87 million, fatalities – 2.22 million (columns 10 and 11). Column 5 lists the total of novel mutations for each country, percentage values related this sum to the total number of mutations. Source for worldwide spread of Covid-19 - https://www.worldometers.info/coronavirus/

The UK data in this Table do not contain results from the analysis of the SARS-CoV-2 variant B.1.1.7 which were shown in Table 1, as of January 20, 2021.



	B. 1. 1.7	B.1.135	P.1	P.2
Gene	Mutation	Mutation	Mutation	Mutation
	T1001I			
ORF1ab	A1708D			
medRxiv prepr	int doi: https://doi.org/10.1101/ e not confiied by bedereview	2021.02.04.21251111; this yersion posted) is the author/funder, who has granted m e available under a CC-BY-NC-ND 4.0 Inf	February 6, 2021, The copyright address to display the r	t holder for this preprint
nsp5	It is mad	e available under a CC-BY-NC-ND 4.0 Int	ernational license	L205V
nsp6				
	H69/V70 del	L18F		
	Y144 del	D80A		
	N501Y	D215G		
Spike	A570D	R246I		
эріке	P681H	K417N	K417N	
	T716I	E484K	E484K	E484K
	S982A	N501Y	N501Y	
	D118H	A701Y		V1176F
	Q27stop			
Orf8	R52I			
	Y73C			
	D3L			A119S
Nucleoconsid	S235F			R203K
Nucleocapsid				G204R
				M234I

Table 1 Mutations associated with variants B.1.1.7, B.1.135, P.1 and P.2

Country	B.1.1.7 (UK variant)	B.1.351 (South Africa Variant)	B.1.1.28 (E484K.V2)
ArgentinadRxiv preprint doi:	https://doi.org/1¶.1101/2021.02.	04.21251111; this versi © n posted February 6, 20 uthor/funder, who has granted medRxiv a licens le under a CC-BY-NC-ND-4.0 International licen 4	121. The copyright holder for this prepret to display the preprint in perpetuity.
Australia	It is made availat 52	He under a CC-BY-NC-ND 4.0 International licen 4	0
Austria	41	0	0
Bangladesh	3	0	0
Belgium	194	12	0
Botswana	0	7	0
Brazil	15	0	175
Canada	2	0	13
China	2	0	0
Czech Republic	12	0	0
Denmark	531	3	6
Faroe Islands	0	0	1
Dominican Republic	1	0	0
Ecuador	1	0	0
Finland	40	2	0
France	221	16	0
Germany	618	82	4
Gibraltar	1	0	0
Greece	5	0	0
Hungary	5	0	0
Iceland	20	0	0
India	23	0	0
Iran	1	0	0
Ireland	159	7	4
Israel	99	0	0
Italy	133	0	5
Jamaica	4	0	0
Japan	36	6	9
Jordan	38	0	0
Kenya	0	2	0
Luxembourg	32	2	1
Malaysia	1	0	0
Mayotte	18	0	0

Mexico	1	0	0	
Mayotte	0	21	0	
Mozambiquach was not co	https://doi.org/18.1101/2021.02. ertified by peel review) is the a It is made availab	04.212511111, this version posted February 6, 20 uthor/funder, who has granted medRxiv a licens le under a CC-BY-NC-ND 4.0 International licen	21. The copyright holder for this pre e to display the preprint in perpetuity se .	eprint /.
Netherlands	320	22	2	
New Zealand	19	6	0	
Nigeria	4	0	0	
Norway	30	1	3	
Oman	1	0	0	
Pakistan	5	0	0	
Panama	0	1	0	
Peru	1	0	0	
Poland	7	0	0	
Portugal	88	1	0	
Romania	9	0	0	
Singapore	38	0	1	
Slovakia	37	0	0	
Slovenia	2	0	0	
South Africa	0	490	0	
South Korea	13	1	1	
Spain	177	1	0	
St. Lucia	3	0	0	
Sweden	15	1	0	
Switzerland	183	11	1	
Thailand	2	0	0	
Trinidad and Tobago	1	0	0	
Turkey	50	0	0	
United Arab Emirates	21	5	0	
United Kingdom	36,643	74	15	
USA	333	1	24	
Vietnam	1	0	0	

Table 2 – Variants by country as of February 1, 2021(https://www.gisaid.org/hcov19-variants)

Table 3 - United Kingdom 01/19/2020 - 01/20/2021 Total Position Location Mutation Percentage

medRxiv p (which for this preprint n perpetuity.

Count

\vdash			G T	Count	
<u>re</u>	printodoi: http	ps://doi.org/10.1101/2021.02.04.21251111; this version po	sted February 6	. 2024./¶he co	pyright holder
N	vas2filohtcerti	fied by peer review) is the ସିଆରor/funder, who has grante lt is made available under a CC-BY-NC-ND 4.	d med Rx il√a lice	ense2to76fisplay	rthe 2≫re0j7rinti
	241nt	It is made available under a CC-BY-NC-ND 4.	D International li	cens _{69,160}	96.81
	445nt	ORF1ab polyprotein → leader protein	$T \rightarrow C$	34,505	48.3
-	1,163nt		A→T	2,544	3.56
H	1,210nt		G→T	1,440	2.02
\vdash		2		,	
L	1,513nt	nsp2	$C \rightarrow T$	1,528	2.14
L	1,947nt		T→C	1,576	2.21
	1,987nt		A→G	3,018	4.22
	3,037nt		$C \rightarrow T$	69,231	96.91
	3,256nt		T→C	2,523	3.53
H	4,002nt		$C \rightarrow T$	1,519	2.13
\vdash					
	4,543nt	nsp3	C→T	1,516	2.12
	6,286nt	1	$C \rightarrow T$	34,650	48.5
	6,807nt		$C \rightarrow T$	2,220	3.11
	7,528nt		$C \rightarrow T$	1,524	2.13
	7,926nt		$C \rightarrow T$	2,818	3.94
	8,683nt		C→T	2,189	3.06
-		mam 4	$C \rightarrow T$	3,640	5.1
_	9,745nt	nsp4			
	9,802nt		G→T	1,449	2.03
	10,097nt	2C liles mustainess	$G \rightarrow A$	2,954	4.13
	10,870nt	3C-like proteinase	$G \rightarrow T$	3,186	4.46
Г	11,083nt		G→T	5,734	8.03
H	11,396nt	1	C→T	2,286	3.2
H	,	nsp6		,	
L	11,533nt	·	A→G	1,960	2.74
	11,781nt		A→G	2,368	3.31
L	12,067nt	nsp7	$G \rightarrow T$	1,709	2.39
	13,536nt		$C \rightarrow T$	1,502	2.1
	14,202nt		G→T	2,522	3.53
-		DNA dependent DNA polymerose	$C \rightarrow T$		96.92
-	14,408nt	RNA-dependent RNA polymerase		69,237	
_	14,805nt		C→T	1,860	2.6
	15,406nt		G→T	2,077	2.91
	18,877nt	21 4- 51	$C \rightarrow T$	3,827	5.36
	19,542nt	3'-to-5' exonuclease	$G \rightarrow T$	2,582	3.61
Т	19,718nt		$C \rightarrow T$	2,645	3.7
H	20,268nt	endoRNAse	A→G	1,999	2.8
H		21.0 21 41.14 6			
-	21,255nt	2'-O-ribose methyltransferase	G→C	34,494	48.28
	21,575nt		$C \rightarrow T$	1,502	2.1
	21,614nt		$C \rightarrow T$	17,561	24.58
	21,637nt		$C \rightarrow T$	2,697	3.78
	22,227nt		$C \rightarrow T$	34,855	48.79
-	22,346nt		G→T	2,244	3.14
-	22,377nt		C→T		
H		Spike glycoprotein		1,518	2.12
L	22,388nt		C→T	2,540	3.56
	22,444nt		$C \rightarrow T$	2,085	2.92
	22,992nt		$G \rightarrow A$	1,636	2.29
	23,403nt		A→G	69,262	96.95
Г	23,731nt		C→T	2,940	4.12
H	24,334nt	1	$C \rightarrow T$	10,442	14.62
H				5,774	
-	25,563nt	•	$G \rightarrow T$		8.08
L	25,614nt	ORF3a	$C \rightarrow T$	2,737	3.83
L	26,060nt	OIG 50	$C \rightarrow T$	2,632	3.68
	26,144nt		$G \rightarrow T$	1,748	2.45
Г	26,424nt	Envelope protein	T→C	1,957	2.74
H	26,735nt		$C \rightarrow T$	3,760	5.26
\vdash		Membrane glycoprotein	C→G	34.459	48.24
-	26,801nt	ODE#		- ,	
L	27,769nt	ORF7b	C→T	2,706	3.79
	27,944nt	ORF8	$C \rightarrow T$	25,177	35.24
l	28,169nt	UKI 0	A→G	2,693	3.77
	28,854nt		$C \rightarrow T$	3,683	5.16
Т	28,881nt	1	G→A	23,975	33.56
۲					
-	28,882nt	•	G→A	23,947	33.52
L	28,883nt	Nucleocapsid phosphoprotein	G→C	23,946	33.52
L	28,932nt	seapoid phosphopiotein	$C \rightarrow T$	34,536	48.34
١	29,227nt		$G \rightarrow T$	2,566	3.59
Г	29,366nt		$C \rightarrow T$	1,743	2.44
	29,466nt	1	$C \rightarrow T$	2,578	3.61
۲		at unstroom downstroom region of ODE10 ODE0		1,466	2.05
\vdash	29,555nt	at upstream downstream region of ORF10 ORF9	$C \rightarrow T$		
L	29,645nt	ORF10	G→T	34,684	48.55
L	29,771nt	3´UTR	A→G	2,475	3.46
		· · · · · · · · · · · · · · · · · · ·			

Table 4A - South Africa 09/01 - 12/07/2020

Position Location Mutation Mutation Mutation Medicing Property of the Count Incidence (which was not certified by peer review) is the author/funder with has granted medRxiv a license to display the preprint in perpetuity.

nichtwas n	ot certified by peer re	eview) is the author/funder, who has granted medRxiv a made available underlanding the hard A Internation	license	ispiay the <u>par</u> ępydnt in pe
241nt	5'UTR	$CG \rightarrow TG$ noneffective	95/95	prevalent
1,059nt		$CC \to TC$ $ACC \text{ (Threonine)} \to ATC \text{ (Isoleucine)}$	10/95	prevalent
2,164nt	nsp2	GA → CA GAGAAG (Glutamic Acid Lysine) → GACAAG (Aspartic Acid Lysine)	11/95	IN
3,037nt		$\begin{array}{c} \text{CT} \rightarrow \text{TT} \\ \text{noneffective} \end{array}$	95/95	prevalent
5,230nt	nsp3	GT → TT AAGTGG (Lysine Tryptophan) → AATTGG (Asparagine Tryptophan)	12/95	DE
6,762nt		$CT \to TT$ $ACT \text{ (Threonine)} \to ATT \text{ (Isoleucine)}$	13/95	unique
10,323nt	3C-like proteinase	$AG \rightarrow GG$	11/95	unique
11,230nt	nsp6	AAG (Lysine) \rightarrow AGG (Arginine) $GC \rightarrow TC$ $ATGCCT (Methionine Proline) \rightarrow ATTCCT (Isoleucine Proline)$	11/95	unique
12,503nt	nsp8	$TA \rightarrow CA$ $TAT (Tyrosine) \rightarrow CAT (Histidine)$	26/95	unique
14,408nt	RNA-dependent RNA polymerase	$CT \rightarrow TT$	95/95	prevalent
20,268nt	endoRNAse	$\begin{array}{c} \operatorname{CCT}\left(\operatorname{Proline}\right) \to \operatorname{CTT}\left(\operatorname{Leucine}\right) \\ \operatorname{AG} \to \operatorname{GG} \\ \operatorname{noneffective} \end{array}$	21/95	FR,ES,RU
21,801nt		$AT \to CT$ $GAT \text{ (Aspartic Acid)} \to GCT \text{ (Alanine)}$	10/95	unique; S501Y.V2
22,675nt		$\begin{array}{c} \text{CG} \rightarrow \text{TG} \\ \text{noneffective} \end{array}$	10/95	unique
22,813nt		$\begin{array}{c} GA \rightarrow TA \\ \text{noneffective} \end{array}$	10/95	DE
23,012nt	Spike glycoprotein	$GA \rightarrow AA$	12/95	IN
23,403nt		$ \begin{array}{c} GAA \text{ (Glutamic Acid)} \rightarrow AAA \text{ (Lysine)} \\ AT \rightarrow GT \\ GAT \text{ (Aspartic Acid)} \rightarrow GGT \text{ (Glycine)} \end{array} $	95/95	prevalent
23,664nt		$GAT \text{ (Aspartic Acid)} \rightarrow GGT \text{ (Glycine)}$ $CA \rightarrow TA$ $GCA \text{ (Alanine)} \rightarrow GTA \text{ (Valine)}$ $GA \rightarrow TA$	14/95	ES,IN
25,563nt		$GA \rightarrow TA$ $CAGAGC$ (Glutamine Serine) $\rightarrow CATAGC$ (Histidine Serine)	10/95	prevalent
25,770nt	ORF3a protein	GC → TC AGGCTT (Arginine Leucine) → AGTCTT (Serine Leucine)	20/95	RU
25,904nt		$CA \rightarrow TA$ $TCA \text{ (Serine)} \rightarrow TTA \text{ (Leucine)}$	10/95	BR,DE
26,456nt	Envelope protein	$CT \to TT$ $CCT \text{ (Proline)} \to CTT \text{ (Leucine)}$	10/95	unique
28,253nt	ORF8 protein	$\begin{array}{c} \text{CA} \rightarrow \text{TA} \\ \text{noneffective} \end{array}$	14/95	BR,DE,ES,FR,US
28,854nt		$CA \rightarrow TA$ $TCA \text{ (Serine)} \rightarrow TTA \text{ (Leucine)}$	23/95	CN,DE,ES,FR,IN,RU
28,881nt	Nucleocapsid phosphoprotein	GGG → AAC AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)	61/95	prevalent
28,887nt		$ \begin{array}{c} \text{CT} \to \text{TT} \\ \text{ACT (Threonine)} \to \text{ATT (Isoleucine)} \end{array} $	11/95	BR,CN,FR,IN,RU
29,721nt	3´UTR	$\begin{array}{c} CC \rightarrow TC \\ \text{noneffective} \end{array}$	26/95	unique

Table 4B - South Africa 01/19/2020 - 01/20/2021

Position Location Mutation Total Persontage

Position Location Count

medRxiv p reprint this://doi.org/10.1101/2021.92.94.21251111; this version posted February 6, 2021 the copyright holder for this preprint (which was 24 but certified by peer review) is the author/funder, who has granted medRxiv a license to 7 display the 9 february in perpetuity.

**This was a published under a CC-RV-NC-ND 4.0 International libense 50. 3.32

p	eprih/74161i: http	s://doi.org/10.1101/2021.9 <mark>գ.</mark> q4,21251111; this version po	sted February 6	2021 ⁸ †he co	pyright holder
h	was2noncerti	ps://doi.org/10.1101/2021.93.64.21251111; this version po fied by peer review) is the author/funder, who has grante biនាក់រង់ប៉ុន្តារាងបុខធ្វើស្រៀល undata ស្រីប៉េង្សីY-NC-ND 4.0	d meɗR x íī√a lice	ense Ito 7 (12splay	the 90% explrint in
	355nt	birermade हुएक्रांक्कीट underea क्रिक्टिंग -NC-ND 4.1) Internatipnal li	cense 59	3.32
	1,059nt		$C \rightarrow T$	149	8.38
	2,094nt	nsp2	$C \rightarrow T$	38	2.14
	2,164nt	nsp2	$G \rightarrow C$	84	4.72
Ī	2,692nt		$A \rightarrow T$	41	2.3
	3,037nt		$C \rightarrow T$	1,746	98.15
Ī	4,002nt		$C \rightarrow T$	165	9.27
Ī	4,093nt		$C \rightarrow T$	48	2.7
Ī	5,230nt	nsp3	$G \rightarrow T$	147	8.26
İ	6,027nt	1	$C \rightarrow T$	46	2.59
Ì	6,762nt		C→T	178	10.01
ŀ	7,064nt		A→G	124	6.97
f	8,660nt		C→T	69	3.88
f	8,964nt	nsp4	C→T	69	3.88
ŀ	9,498nt	p .	T→C	36	2.02
ŀ	10,097nt		G→A	163	9.16
ŀ	10,323nt	3C-like proteinase	A→G	169	9.5
ŀ	11,083nt		$G \rightarrow T$	60	3.37
ŀ	11,003nt 11,230nt	nsp6	$G \rightarrow T$	75	4.22
ŀ	11,230nt 11,447nt	поро	$G \rightarrow A$	129	7.25
ŀ	12,503nt	nsp8	$T \rightarrow C$	389	21.87
ŀ	13,536nt	нэро	C→T	170	9.56
ŀ	13,330nt 14,408nt	RNA-dependent RNA polymerase	$C \rightarrow T$	1,773	9.56
ŀ	14,408nt 14,925nt	ra a dependent ravas porymerase	$C \rightarrow T$	71	3.99
-	16,376nt		$C \rightarrow T$	54	3.04
-	16,490nt		$C \rightarrow T$	39	2.19
-	16,853nt	Helicase	G→T	47	2.64
ŀ	16,946nt		$C \rightarrow T$	43	2.42
ŀ	18,747nt	3'-to-5' exonuclease	$C \rightarrow T$	115	6.46
ŀ	20,234nt	3-to-3 exoluclease	$C \rightarrow T$	42	2.36
ŀ	20,234nt 20,268nt	endoRNAse	A→G	209	11.75
ŀ	21,801nt		A→C	142	7.98
ŀ	22,206nt		A→G	71	3.99
-	22,287nt		$T \rightarrow A$	86	4.83
ŀ	22,287nt 22,299nt		$G \rightarrow T$	69	3.88
ŀ	22,675nt		$C \rightarrow T$	290	16.3
ŀ	22,813nt		G→T	139	7.81
ŀ	23,012nt	Spike glycoprotein	$G \rightarrow A$	146	8.21
ŀ	23,063nt			140	7.87
-	,		$A \rightarrow T$		
ŀ	23,403nt		A→G	1,772	99.61
ŀ	23,625nt		$C \rightarrow T$ $C \rightarrow T$	53 154	2.98
ŀ	23,664nt				8.66
ŀ	23,731nt 25,455nt		$C \rightarrow T$ $G \rightarrow T$	161	9.05
ŀ				65 66	3.65
ŀ	25,521nt	ODE2-	$C \rightarrow T$		3.71
ŀ	25,563nt	ORF3a	$G \rightarrow T$	148	8.32
ļ	25,770nt		G→T	285	16.02
ŀ	25,904nt	Envolone	$C \rightarrow T$	143	8.04
ŀ	26,456nt	Envelope protein	$C \rightarrow T$	140	7.87
ŀ	26,586nt	Membrane glycoprotein	C→T	62	3.49
ŀ	27,384nt	ORF6	T→C	120	6.75
ļ	27,504nt	ORF7a	T→C	50	2.81
ļ	28,077nt	ORF8	G→T	74	4.16
ļ	28,253nt	-	C→T	178	10.01
ļ	28,854nt		C→T	173	9.72
ļ	28,881nt		G→A	1,238	69.59
ļ	28,882nt	Nucleocapsid phosphoprotein	G→A	1,238	69.59
ļ	28,883nt	···r····r····r····r····r····r····r······	G→C	1,238	69.59
ļ	28,887nt		C→T	152	8.54
ļ	29,425nt		G→T	117	6.58
Ĺ	29,721nt	3´UTR	$C \rightarrow T$	388	21.81

Table 5A -	Brazil		02/25 - 08/15/2020		
Rxiv ipasepoin t	doi: https ://deitorg /10.1101/	2021.02.04.21251111; this warsion posted February 6, 202	1. T ტადი pyri	h theider der	this p
which was no 241nt	ot certified by peer review 5 UTR It is mad) is the author/funder, who has pranted medRxiv a license e available under a CC-BY-NC-ND 4.0 International license	to display the	preprint in pe prevalent	rpetui
3,037nt	nsp3	$\begin{array}{c} \text{CT} \rightarrow \text{TT} \\ \text{noneffective} \end{array}$	97/102	prevalent	
12,053nt	nsp7	$CT \rightarrow TT$ $CTT \text{ (Leucine)} \rightarrow TTT \text{ (Phenylalanine)}$	16/102	unique	
14,408nt	RNA-dependent RNA polymerase	$CT \to TT$ $CCT \text{ (Proline)} \to CTT \text{ (Leucine)}$	96/102	prevalent	
23,403nt	Spike glycoprotein	$AT \to GT$ $GAT \text{ (Aspartic Acid)} \to GGT \text{ (Glycine)}$	97/102	prevalent	
25,088nt	Spike grycoprotein	$GT \to TT$ $GT \to TT \text{ (Valine)} \to TT \text{ (Phenylalanine)}$	25/102	unique	
27,299nt	ORF6 protein	$TA \rightarrow CA$ $ATA \text{ (Isoleucine)} \rightarrow ACA \text{ (Threonine)}$	41/102	FR	
28,881nt	Nucleocapsid	GGG → AAC AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)	73/102	prevalent	
29,148nt	phosphoprotein	$ \begin{array}{c} TC \to CC \\ ATC \text{ (Isoleucine)} \to ACC \text{ (Threonine)} \end{array} $	41/100	FR,RU	

Table :	5B - Bi	razil	01/19/2020 -	01/19/2020 - 01/20/2021		
Posit		Location	Mutation	Total Count	Percentage	
xiv preprint5d	ii: htt	ps://doi.org/10.1101/2021.02.04.21251111; this version po fied by peer review) is the author/funder, who has grante It is made available under a CC-BY-NC-ND 4.	sted l^Tebr tarv 6	2021 ⁴³ The co	pvriaht ⁸ 9older	for this prepr
hich was 200	nt cert	fied by peer review) is the author/funder, who has grante	d međRxtv a lice	ense t@3display	the presprint in	n perpetuity.
100:	nt	It is made available under a CC-BY-NC-ND 4.) Internatipnal li	cense 97	8.77	
241:	nt		$C \rightarrow T$	1,087	98.28	
3,037	7nt		$C \rightarrow T$	1,093	98.82	
3,760	6nt	nsp3	$T \rightarrow C$	49	4.43	
6,319	9nt		A→G	32	2.89	
10,66	7nt	3C-like proteinase	T→G	98	8.86	
11,08	3nt		$G \rightarrow T$	29	2.62	
11,82	24nt	nsp6	$C \rightarrow T$	98	8.86	
12,05	3nt	nsp7	$C \rightarrow T$	318	28.75	
12,96	4nt	nsp9	A→G	89	8.05	
14,40	8nt	RNA-dependent RNA polymerase	$C \rightarrow T$	1,091	98.64	
23,01	2nt	•	G→A	98	8.86	
23,40	3nt	Spike glycoprotein	A→G	1,093	98.82	
25,08	88nt	1 5 7 1	G→T	463	41.86	
26,14	9nt	ORF3a	T→C	31	2.8	
27,29	9nt	ORF6	T→C	459	41.5	
28,25	3nt	ORF8	$C \rightarrow T$	110	9.95	
28,62	28nt		$G \rightarrow T$	99	8.95	
28,88	31nt		G→A	1,031	93.22	
28,88	2nt		G→A	1,031	93.22	
28.88		Nucleocapsid phosphoprotein	G→C	1.031	93.22	
28,97			G→T	101	9.13	
29,14			T→C	466	42.13	
29,75			$C \rightarrow T$	95	8.59	
29,86		3´UTR	G→T	33	2.98	

Table 6A -	US		US-I 02/29 - 04/26/2020*	US-II 06/12 - 07/07/2020*	US-III 07/09 - 07/22/2020	US-IV 08/01 - 12/01/2020	
Position	Location	Mutation	Count	Count	Count	Count	Incidence
241nt	5 UTR	$CG \rightarrow TG$ noneffective	76/111	74/96	99/99	116/117	prevalent
1,059nt		$CC \rightarrow TC$ $ACC \text{ (Threonine)} \rightarrow ATC \text{ (Isoleucine)}$	42/112	45/97	30/99	56/117	prevalent
1,917nt	nsp2	$CT \to TT$ $ACT \text{ (Threonine)} \to ATT \text{ (Isoleucine)}$	0/112	11/97	0/99	0/117	CN
2,416nt		$CA \rightarrow TA$ noneffective	9/112	4/97	1/99	3/117	CN,ES,FR,RU,ZA
3,037nt		$CT \rightarrow TT$ noneffective	75/112	72/97	99/99	117/117	prevalent
3,871nt		$GA \rightarrow TA$ $AAGATC$ (Lysine Isoleucine) $\rightarrow AATATC$ (Asparagine Isoleucine)	0/112	0/97	29/99	4/117	FR,ZA
3,931nt		$TG \rightarrow CG$ noneffective	0/112	0/97	29/99	4/117	unique
4,226nt	nsp3	$CC \rightarrow TC$ $CCA (Proline) \rightarrow TCA (Serine)$	0/112	0/97	28/99	0/117	unique
5,672nt	nsp3	$CC \rightarrow TC$ $CCT (Proline) \rightarrow TCT (Serine)$	0/112	0/97	28/99	0/117	unique
7,837nt		$AG \rightarrow CG$ $TTAGAC$ (Leucine Aspartic Acid) $\rightarrow TTCGAC$ (Phenylalanine Aspartic Acid)	0/112	0/97	28/99	0/117	CN
8,083nt		$\begin{array}{c} GG \rightarrow AG \\ ATGGAA \text{ (Methionine Glutamic Acid)} \rightarrow ATAGAA \text{ (Isoleucine Glutamic Acid)} \\ Acid) \end{array}$	0/112	0/97	0/99	18/117	unique
8,782nt	nsp4	$ CC \rightarrow TC $ noneffective	15/112	15/97	0/99	0/117	CN,DE,ES,IN
10,139nt	3C-like proteinase	$CT \rightarrow TT$ $CTT \text{ (Leucine)} \rightarrow TTT \text{ (Phenylalanine)}$	0/112	0/97	0/99	29/117	unique
12,025nt	nsp7	$CA \rightarrow TA$ noneffective	0/112	0/97	11/99	2/117	unique
14,408nt	RNA-dependent RNA polymerase	$CT \rightarrow TT$ $CCT \text{ (Proline)} \rightarrow CTT \text{ (Leucine)}$	78/112	71/97	99/99	117/117	prevalent
17,747nt	helicase	$CT \rightarrow TT$ $CCT \text{ (Proline)} \rightarrow CTT \text{ (Leucine)}$	8/112	12/97	0/99	0/117	FR
17,858nt	nenease	$AT \rightarrow GT$ $TAT \text{ (Tyrosine)} \rightarrow TGT \text{ (Cysteine)}$	8/112	12/97	0/99	0/117	ZA
18,060nt		$CT \rightarrow TT$ noneffective	9/112	11/97	0/99	0/117	ZA
18,424nt	3'- to – 5'exonuclease	$AA \rightarrow GA$ $AAT (Asparagine) \rightarrow GAT (Aspartic Acid)$	0/112	0/97	0/99	26/117	unique
18,486nt	3 - to - 3 exolucioase	$CA \rightarrow TA$ noneffective	0/112	0/97	13/99	2/117	unique
18,877nt		$CT \rightarrow TT$ noneffective	13/112	1/97	6/99	3/117	BR,DE,ES,FR,IN
19,677nt		$GG \rightarrow TG$ $CAGGGT (Glutamine Glycine) \rightarrow CATGGT (Histidine Glycine)$	0/112	0/97	26/99	0/117	unique
19,839nt	endoRNAse	$TA \rightarrow CA$ noneffective	0/112	0/97	11/99	7/117	CN,DE,ES,FR,RU
20,268nt		$ AG \rightarrow GG $ noneffective	2/112	5/97	15/99	29/117	FR,ES,RU,ZA
21,304nt	2'-O-ribose methyltransferase	$CG \rightarrow TG$ $CGC (Arginine) \rightarrow TGC (Cysteine)$	0/112	0/97	0/99	25/117	ES
22,162nt	•	$TT \rightarrow CT$ noneffective	0/112	0/97	13/99	2/117	unique
23,403nt	Spike glycoprotein	$AT \rightarrow GT$ GAT (Aspartic Acid) $\rightarrow GGT$ (Glycine)	77/112	72/97	99/99	117/117	prevalent
23,707nt		$CA \rightarrow TA$ noneffective	0/112	0/97	11/99	3/117	unique
25,907nt	ODE2at-i	$GT \rightarrow TT$ $GGT (Glycine) \rightarrow GTT (Valine)$	0/112	0/97	0/99	26/117	unique
25,563nt	ORF3a protein	GA → TA CAGAGC (Glutamine Serine) → CATAGC (Histidine Serine)	65/112	54/97	37/99	66/117	prevalent
27,964nt	ORF8 protein	$CA \rightarrow TA$ $TCA \text{ (Serine)} \rightarrow TTA \text{ (Leucine)}$	13/112	6/97	4/99	31/117	unique
·				US-II 06/12 -	US-III 07/09 -	US-IV 08/01 -	

Table 5A –	·US		US-I 02/29 - 04/26/2020*	07/07/2020*	07/22/2020	12/01/2020	
Position	Location	Mutation	Count	Count	Count	Count	Incidence
28,144nt	ORF8 protein	$TA \rightarrow CA$ $TTA \text{ (Leucine)} \rightarrow TCA \text{ (Serine)}$	15/112	15/97	0/99	0/117	CN,DE,ES,IN
28,472nt		$CC \to TC$ $CCT (Proline) \to TCT (Serine)$	0/112	0/97	0/99	22/117	unique
28,821nt		$CT \to AT$ $TCT (Serine) \to TAT (Tyrosine)$	0/112	0/97	9/99	5/117	unique
28,854nt		$CA \rightarrow TA$ $TCA \text{ (Serine)} \rightarrow TTA \text{ (Leucine)}$	3/112	0/97	13/99	28/117	CN,DE,ES,FR,IN,RU
28,869nt	Nucleocapsid phosphoprotein	$CA \rightarrow TA$ $CCA (Proline) \rightarrow CTA (Leucine)$	0/112	0/97	0/99	25/117	DE
28,881nt		GGG → AAC AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)	3/112	1/97	17/99	17/117	prevalent
28,887nt		$CT \to TT$ $ACT \text{ (Threonine)} \to ATT \text{ (Isoleucine)}$	0/112	1/97	1/99	10/117	BR,CN,FR,IN,RU
28,977nt		$CT \rightarrow TT$ $TCT (Serine) \rightarrow TTT (Phenylalanine)$	0/112	0/97	29/99	4/117	CN

Table 6B - US 01/19/2020 - 01/20/2021 **Total** Position Location Mutation Percentage Count medRxiv p eprintethi: https://doi.org/10.1101/2021.92.94.21251111; this version posted February 6 2024.19he copyright holder for this preprint (which was 24 butcert fied by peer review) is the author/funder, who has granted medRxiv a licenseth 80 is play the preprint in perpetuity.

833nt It is made available under a CC-BY-NC-ND 4.0 International license 171 2.21

COT 28 844 54 49 54.49 1,059nt 28,844 3,037nt $C \rightarrow T$ 49,077 92.71 nsp3 8,083nt $G \rightarrow A$ 2,779 5.25 $C \rightarrow T$ $C \rightarrow T$ 2,798 5.29 8,782nt nsp4 15.99 10,319nt 8,465 10,323nt A→G 1,176 2.22 3C-like proteinase $C \rightarrow T$ 2.12 10,741nt 1,120 11,083nt $G \rightarrow T$ 1,612 3.05 nsp6 11,916nt $C \rightarrow T$ 1,670 3.15 nsp7 14,408nt $C \rightarrow T$ 49,140 92.83 RNA-dependent RNA polymerase 14,805nt $C \rightarrow T$ 3,176 6 16,260nt $C \rightarrow T$ 1,797 3.39 17,747nt $C \rightarrow T$ 2,049 3.87 Helicase 17,858nt $A \rightarrow G$ 2,084 3.94 18,060nt $C \rightarrow T$ 2,135 4.03 12.67 18,424nt 3'-to-5' exonuclease $A \rightarrow G$ 6,708 18,877nt $C \rightarrow T$ 1,517 2.87 T→C 3.69 19,839nt 1,955 endoRNAse 20,268nt A-→G 6,742 12.74 21,304nt $C \rightarrow T$ 12.47 2'-O-ribose methyltransferase 6.603 23,403nt A→G 49,154 92.86 23,604nt Spike glycoprotein $C \rightarrow A$ 1,238 2.34 24,076nt $T \rightarrow C$ 2,148 4.06 25,563nt 31,241 59.02 $G \rightarrow T$ ORF3a 25,907nt $G \rightarrow T$ 6,369 12.03 $C \rightarrow T$ $T \rightarrow C$ 22.67 5.27 12,002 27,964nt ORF8 2,790 28,144nt 28,472nt $C \rightarrow T$ 6,473 12.23 28,821nt $C \rightarrow A$ 1,821 3.44 28,842nt $G \rightarrow T$ 1,152 2.18 28,854nt $C \rightarrow T$ 6,694 12.65 28,869nt $C \rightarrow T$ 6,640 12.54 Nucleocapsid phosphoprotein 6,887 13.01 28,881nt $G \rightarrow A$

3'UTR

 $G \rightarrow A$

G→C

 $C \rightarrow T$

 $G \rightarrow T$

 $C{\rightarrow}T$

 $C \rightarrow A$

6,848

6,847

1,090

1,630

1,062

1,990

12.94 12.93

2.06

3.08

2.01

3.76

28,882nt

28,883nt

28,887nt

29,402nt

29,784nt

29,870nt

Table 7A -			IN-I 01/27 - 05/27/2020*	IN-II 06/03 - 07/04/2020	
Position edRxiv pre	Location print doi: https://doi.org/10.1	Mutation 101/2021.02.04.2125(1.11; المادة version posted Fe	Count bruary 6, 2021.	Count The copyright	Incidence holder for this pre
(24high w	as not certificateby peer re	Mutation 101/2021.02.04.2125.1111; this version posted Fe view) is the author/funder, who has granted medF made available under fire UNY-NC-ND 4.0 Intern	exiva ligograse to	displooys∕nome pre	printievate inetuity
2,292nt	nsp2	AG \rightarrow CG CAG (Glutamine) \rightarrow CCG (Proline)	0/99	22/98	unique
2,836nt		$CT \rightarrow TT$ noneffective	23/99	44/98	unique
3,037nt		$CT \rightarrow TT$ noneffective	81/99	96/98	prevalent
3,634nt	nsp3	$CA \rightarrow TA$ noneffective	8/99	17/98	ZA
4,084nt	пѕрз	$CA \rightarrow TA$ noneffective	12/99	1/98	ZA
4,300nt		$\begin{array}{c} GC \rightarrow TC \\ noneffective \end{array}$	0/99	16/98	unique
6,312nt		$CA \rightarrow AA$ $ACA \text{ (Threonine)} \rightarrow AAA \text{ (Lysine)}$	10/99	0/98	US
11,083nt	nsp6	GT → TT TTGTAT (Leucine Tyrosine) → T TT (Phenylalanine)	13/99	0/98	BR,CN,DE, ES,FR,US,Z A
14,408nt	RNA-dependent RNA	$CT \rightarrow TT$ $CCT (Proline) \rightarrow CTT (Leucine)$	80/99	91/98	prevalent
15,324nt	polymerase	$CA \rightarrow TA$ noneffective	7/99	18/98	B,C,G,F
16,512nt	helicase	$AT \rightarrow GT$ noneffective	0/99	11/98	unique
18,568nt		$CT \rightarrow TT$ $CTC (Leucine) \rightarrow TTC (Phenylalanine)$	0/99	22/98	unique
18,877nt	3'- to - 5'exonuclease	$CT \rightarrow TT$ noneffective	45/99	51/98	BR,DE,ES, FR,US
19,154nt		$CA \rightarrow TA$ ACA (Threonine) $\rightarrow ATA$ (Isoleucine)	0/99	12/98	unique
21,724nt		GT → TT TTGTTC (Leucine Phenylalanine) → TTTTTC (Phenylalanine Phenylalanine)	6/99	23/98	RU
22,444nt	Spike glycoprotein	$ \begin{array}{c} CC \to TC \\ \text{noneffective} \end{array} $	26/99	48/98	US
23,403nt		$AT \rightarrow GT$ GAT (Aspartic Acid) $\rightarrow GGT$ (Glycine)	80/99	96/98	prevalent
23,929nt		$CA \rightarrow TA$ noneffective	10/99	0/98	FR,RU,US
25,563nt	ORF3a protein	$GA \rightarrow TA$ $CA GA GC (Glutamine Serine) \rightarrow CA TA GC$ (Histidine Serine)	43/99	51/98	prevalent
26,735nt	Membrane glycoprotein	$CA \rightarrow TA$ noneffective	39/99	49/98	DE,ES,FR, US
28,311nt		$CC \rightarrow TC$ $CCC \text{ (Proline)} \rightarrow CTC \text{ (Leucine)}$	10/99	0/98	unique
28,854nt	Nucleocapsid phosphoprotein	$CA \to TA$ $TCA \text{ (Serine)} \to TTA \text{ (Leucine)}$	29/99	41/98	CN,DE,ES, FR,RU,US,Z

Table 7B - India 01/19/2020 - 01/20/2021 Total Position Location Mutation Percentage Count medRxiv p eprift bibi: https://doi.org/10.1101/2021.52/GR21251111: this version posted February 6 2024.81the copyright holder for this preprint (which washbutcert fied by peep Review place and the interpretation of the 2,292nt 2.23 $A \rightarrow C$ 73 2,836nt $C \rightarrow T$ 281 8.57 3,037nt $C{\rightarrow}T$ 2,824 86.18 3,634nt $C \rightarrow T$ 283 8.64 2.14 4,300nt $G \rightarrow T$ 70 4,354nt $G \rightarrow A$ 227 6.93 nsp3 4,372nt 72 2.2 A→G 5,700nt $C \rightarrow A$ 949 28.96 C→A 9.22 6.312nt 302 6,573nt $C \rightarrow T$ 228 6.96 8,782nt $C \rightarrow T$ 74 2.26 3.72 8,917nt nsp4 $C \rightarrow T$ 122 $C \rightarrow T$ 4.76 9,693nt 156 11,083nt nsp6 $G \rightarrow T$ 369 11.26 $C \rightarrow T$ $C \rightarrow T$ 13,730nt 332 10.13 2,768 14,408nt RNA-dependent RNA polymerase 84.47 15,324nt $C \rightarrow T$ 285 8.7 $C \rightarrow T$ 143 4.36 16,626nt Helicase 18,568nt $C \rightarrow T$ 71 2.17 18,877nt 654 19.96 3'-to-5' exonuclease $C \rightarrow T$ 19,524nt $C \rightarrow T$ 69 2.11 21,550nt $A \rightarrow C$ 115 3.51 2'-O-ribose methyltransferase 21,551nt $A \rightarrow T$ 112 3.42 21,724nt 3.33 $G \rightarrow T$ 109 22,444nt $C \rightarrow T$ 507 15.47 22,468nt Spike glycoprotein $G \rightarrow T$ 76 2.32 23,403nt 2,832 86.42 $A \rightarrow G$ 23,929nt $C \rightarrow T$ 298 9.09 222 25,528nt $C \rightarrow T$ 6.77 ORF3a 25,563nt $G \rightarrow T$ 652 19.9 $C \rightarrow T$ 26,735nt Membrane glycoprotein 19.96 654 27,384nt ORF6 $T \rightarrow C$ 77 2.35 ORF8 $T \rightarrow C$ 73 2.23 28,144nt 9.12 28,311nt $C \rightarrow T$ 299 28,854nt $C \rightarrow T$ 541 16.51 28,878nt $G \rightarrow A$ 70 2.14 1,434 28,881nt Nucleocapsid phosphoprotein G→A 43.76 28,882nt $G \rightarrow A$ 1,430 43.64 28,883nt $G \rightarrow C$ 1,430 43.64 29,474nt $G \rightarrow T$ 72 2.2

 $C \rightarrow T$

 $G \rightarrow A$

 $C \rightarrow A$

74

351

154

2.26

10.71

4.7

3´UTR

at downstream region of ORF10

29,750nt

29,868nt

29,870nt

	Table 8A -	Russia	03/24 - 06/07/2020			
edRxiv p (which	Position reprint doi: h was4not ce	Location ttps://doi.org/10.1101/2021.02 rtified by pserreview) is the	Mutation :04.212511111; this yersion posted February C author/funder, who has granted medRxiv a lic ble under a CC-BNOWER WYS O International li	Count 2021. The co ense to/glissplay	Incidence pyright holder therevelerint in	for this pre
	3,037nt	It is made availa	$CT \to TT$ noneffective	224/226	prevalent	
	3,140nt	nsp3	$CC \rightarrow TC$ $CCT (Proline) \rightarrow AATCTT (Asparagine Leucine)$	13/226	unique	
	14,408nt	RNA-dependent RNA polymerase	$CT \to TT$ $CCT (Proline) \to CTT (Leucine)$	225/226	prevalent	
	20,268nt	endoRNAse	$AG \rightarrow GG$ noneffective	32/226	ES,FR,US, ZA	
	23,403nt	Spike glycoprotein	$AT \rightarrow GT$ $GAT (Aspartic Acid) \rightarrow GGT (Glycine)$	226/226	prevalent	
	25,563nt	ORF3a protein	$GA \rightarrow TA$ $CAGAGC$ (Glutamine Serine) $\rightarrow CATAGC$ (Histidine Serine)	10/226	prevalent	
	26,750nt	Membrane glycoprotein	$CA \rightarrow TA$ noneffective	45/226	unique	
	27,415nt	ORF6 protein	$GC \rightarrow TC$ $GCA (Alanine) \rightarrow TCA (Serine)$	10/226	unique	
	28,881nt	Nucleocapsid phosphoprotein	$GGG \rightarrow AAC$ $AGGGGA$ (Arginine Glycine) $\rightarrow AAACGA$ (Lysine Arginine)	172/226	prevalent	

	Table 8B - Ru	ssia		01/19/2020	- 01/20/2021	
	Position	Location	Mutation	Total Count	Percentage	
iv pre	eprinît ^O doi: http	s://doi.org/10.1101/2021.93.64.21251111; this version po ied by peer review) is the author/funder, who has grante It is made available under a CC-BY-NC-ND 4.	sted Pebruary 6	202157The co	pvria h t ⁷ holder	for this pred
nich v	was2noticertif	ied by peer review) is the author/funder, who has grante	d meɗR x il√a lice	ense t ol 67 spla	y the 957 <i>€</i> p3rintir	n perpetuity.
	1,059nt	It is made available under a CC-BY-NC-ND 4.	0 Internatipnal li	cense 31	2.59	
	3,037nt		$C \rightarrow T$	1,188	99.08	
	3,177nt		C→T	28	2.34	
	3,373nt	nsp3	C→A	43	3.59	
	6,874nt	•	T→G	72	6.01	
	6,883nt		$C \rightarrow T$	38	3.17	
	8,887nt	nsp4	A→G	108	9.01	\neg
	11,029nt	,	G→A	41	3.42	
	11,083nt	nsp6	G→T	32	2.67	
	12,316nt	nsp8	A→G	28	2.34	
	12,886nt	nsp9	A→G	39	3.25	
	13,599nt	•	T→C	63	5.25	
	14,408nt	RNA-dependent RNA polymerase	C→T	1,180	98.42	
	15,540nt	1 1 2	C→T	29	2.42	
	19,839nt	1.7371	T→C	105	8.76	
	20,268nt	endoRNAse	A→G	47	3.92	
	21,724nt		G→A	38	3.17	
	21,772nt		$C \rightarrow T$	41	3.42	
	22,020nt	Spike glycoprotein	T→C	73	6.09	
	23,403nt		A→G	1,195	99.67	
	25,563nt	ORF3a	$G \rightarrow T$	43	3.59	
	26,750nt	Membrane glycoprotein	C→T	53	4.42	
	27,415nt	ORF7a	G→T	34	2.84	
F	28,253nt	ORF8	C→T	32	2.67	
	28,881nt		G→A	1,079	89.99	
	28,882nt		G→A	1,079	89.99	
F	28,883nt	Nucleocapsid phosphoprotein	G→C	1,075	89.66	
	28,905nt	······································	$C \rightarrow T$	62	5.17	
F	28,975nt		G→T	24	2	
-	29,518nt	ORF10	$C \rightarrow T$	49	4.09	

Table 9A -	France		04 – 09/12/2020		
Position	Location		Count	. Incidence.	
Rxiv prep	Location rint doi: https://doi.org/10.1101/2	Mutation 021.02.04.21251111; this version posted February 6, 2021. is the author/funder, who has granted medRxiv a license to available under a CC-BIORET SUPER O International license.	The copyright	holder for this pr	
(ARITHATIN AA O	It is made	available under a CC-BNONET OF D International license	ա շարգայան անագր	ebuilit@walkettherau	
1,059nt		$CC \rightarrow TC$	16/116	prevalent	
-	nsp2	$\frac{ACC \text{ (Threonine)} \rightarrow ATC \text{ (Isoleucine)}}{CA \rightarrow TA}$		CM ECD DII	
2,416nt		$CA \rightarrow 1A$ noneffective	25/116	CN,ESP,RU, US,ZA	
2.025		$CT \to TT$	445/445	·	
3,037nt		noneffective	115/116	prevalent	
4,543nt		$CA \rightarrow TA$	15/116	DE,ES	
1,0 10110		CAC (Histidine) → TAC (Tyrosine)	15/110	22,23	
5,629nt	nsp3	$GT \rightarrow TT$ noneffective	15/116	DE,ES	
		GG → TG			
8,371nt		$CAGGTA$ (Glutamine Valine) $\rightarrow CATGTA$ (Histidine	23/116	ES,RU	
		Valine)		, -	
Ţ.,		$GT \rightarrow TT$		I	
9,526nt	nsp4	ATGTCA (Methionine Serine) → ATTTCA (Isoleucine	15/116	DE,ES	
		$\begin{array}{c} \text{Serine)} \\ \text{CT} \rightarrow \text{TT} \end{array}$	-	 	
11,497nt	nsp6	$CI \rightarrow II$ noneffective	15/116	DE,ES	
12.002		$GC \rightarrow TC$	15/116	DE EG	
13,993nt		GCT (Alanine) $\rightarrow TCT$ (Serine)	15/116	DE,ES	
14,408nt		$CT \rightarrow TT$	114/116	prevalent	
11,100111	RNA-dependent RNA	$CCT (Proline) \rightarrow CTT (Leucine)$	11 1/110	prevalent	
15,324nt	polymerase	$CA \rightarrow TA$	22/116	BR,CN,IN	
		noneffective $GT \to TT$			
15,766nt		$\frac{\text{GT} \text{G (Valine)} \rightarrow \text{TT} \text{G (Leucine)}}{\text{TT} \text{G (Leucine)}}$	15/116	DE,ES	
16,000 4		$AA \rightarrow GA$	15/116	DE EG	
16,889nt	AAA (Lysine) $\rightarrow AGA$ (Arginine)		15/116	DE,ES	
	helicase	$GT \rightarrow TT$			
17,019nt		GAGTTT (Glutamine Acid Phenylalanine) → GATTTT	15/116	DE,ES	
		(Aspartic Acid Phenylalanine) AG → GG		ES,RU,US,	
20,268nt	endoRNAse	noneffective	13/116	ZA	
22.002.4		$GC \rightarrow AC$	15/116		
22,992nt	Spike glycoprotein	$ \frac{AGC \text{ (Serine)} \rightarrow AAC \text{ (Asparagine)}}{AT \rightarrow GT} $	15/116	DE,US	
23,403nt	Spike grycoprotein		116/116	prevalent	
20,100111		$GAT (Aspartic Acid) \rightarrow GGT (Glycine)$		provincin	
25,563nt		GA → TA CAGAGC (Glutamine Serine) → CATAGC (Histidine	57/116	prevalent	
20,000III	ORF3a protein	Serine)	3//110	prevalent	
25 710mt	p.o.co	CT → TT	16/116	DE EC	
25,710nt		noneffective	10/116	DE,ES	
26,735nt		$CA \rightarrow TA$	15/116	DE,ES,IN,	
-,	Membrane glycoprotein	noneffective $TC \rightarrow CC$		US	
26,876nt		$1C \rightarrow CC$ noneffective	15/116	DE,ES	
20.022		CA → TA	10// -		
28,833nt		$T_{\mathbf{CA}}^{\mathbf{CA}}$ (Serine) \to $T_{\mathbf{A}}^{\mathbf{TA}}$ (Leucine)	12/116	ES	
28,851nt		$GT \rightarrow TT$	10/116	IN	
20,03 IIII		AGT (Serine) $\rightarrow ATT$ (Isoleucine)	10/110	111	
20 001 /		GGG → AAC	17/11/		
28,881nt	Nucleocapsid phosphoprotein	AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)	17/116	prevalent	
		$\begin{array}{c} \text{Argmine}) \\ \text{GT} \rightarrow \text{CT} \end{array}$			
28,975nt		$ATGTCT$ (Methionine Serine) $\rightarrow ATCTCT$ (Isoleucine	15/116	DE,ES,IN	
		Serine)		,,	
29,399nt		$GC \rightarrow AC$	15/116	DE,ES	
27,377III		GCT (Alanine) $\rightarrow ACT$ (Threonine)	13/110	DL,E3	

Table 9B - France 01/19/2020 - 01/20/2021

Position Location Mutation Total Count Percentage

medRxiv p repriat deli: https://doi.org/10.1101/2021.92.94.21251111; this version posted February 6 2021 of he copyright holder for this preprint (which was 24 object field by peer review) is the author/funder, who has granted medRxiv a license 26 000 splay the preprint in perpetuity.

repriA₽∂Modi: https	:://doi.org/10.1101/2021.92,94,21251111; this version po	sted February 6	2021 ^{1.0} Phe co	pyright ⁷ holdei
was24outcertifi	ed by peer review) is the author/funder, who has grante It is made available under a CC-BY-NC-ND 4.	d meɗR x iv a lic	ense2io6040isplay	the p@eprinti
	It is made available under a CC-BY-NC-ND 4.0 ORF1ab polyprotein → leader protein) Internatipnal li	cense 55	
445nt	Okt rao poryprotein 7 leader protein	T→C	163	6.14
1,059nt	nsp2	C→T	385	14.51
2,416nt	nsp2	$C \rightarrow T$	320	12.06
3,037nt		$C \rightarrow T$	2,606	98.23
3,099nt		$C \rightarrow T$	69	2.6
4,543nt		$C \rightarrow T$	666	25.1
4,960nt		G→T	69	2.6
4,965nt		$C \rightarrow T$	69	2.6
5,170nt	2	$C \rightarrow T$	53	2
5,629nt	nsp3	$G \rightarrow T$	666	25.1
6,070nt		$C \rightarrow T$	70	2.64
6,286nt		$C \rightarrow T$	168	6.33
7,303nt		C→T	70	2.64
7,564nt		C→T	71	2.68
8,371nt		G→T	233	8.78
9,246nt		$C \rightarrow T$	69	2.6
9,526nt	nsp4	$G \rightarrow T$	667	25.14
10,279nt		$C \rightarrow T$	70	2.64
10,279ht 10,301nt		$C \rightarrow I$	69	2.6
10,525nt	3C-like proteinase	$C \rightarrow A$ $C \rightarrow T$	70	2.64
10,582nt	SC-nkc proteinase	$C \rightarrow T$	113	4.26
10,582nt 10,688nt		$G \rightarrow T$	69	2.6
11,083nt		$G \rightarrow I$ $G \rightarrow T$	99	3.73
	mam 6	$G \rightarrow T$	54	
11,132nt 11,497nt	nsp6	$C \rightarrow T$		2.04 25.1
	7		666 96	
11,851nt	nsp7	$G \rightarrow T$		3.62
13,993nt		$G \rightarrow T$	664	25.03
14,230nt		C→A	68	2.56
14,408nt	RNA-dependent RNA polymerase	$C \rightarrow T$	2,606	98.23
15,324nt	1 1 2	C→T	467	17.6
15,738nt		C→T	63	2.37
15,766nt		G→T	667	25.14
16,889nt	Helicase	A→G	665	25.07
17,019nt		G→T	665	25.07
18,877nt	3'-to-5' exonuclease	C→T	675	25.44
20,268nt	endoRNAse	A→G	111	4.18
21,255nt	2'-O-ribose methyltransferase	G→C	167	6.29
21,800nt		G→T	72	2.71
22,227nt	Spike glycoprotein	$C \rightarrow T$	172	6.48
22,992nt	Spike grycoprotein	G→A	666	25.1
23,403nt		A→G	2,607	98.27
25,563nt		$G \rightarrow T$	1,474	55.56
25,688nt	ORF3a	$C \rightarrow T$	56	2.11
25,710nt		$C \rightarrow T$	677	25.52
26,735nt		$C \rightarrow T$	670	25.25
26,801nt	Membrane glycoprotein	C→G	167	6.29
26,876nt		T→C	667	25.14
27,632nt	ORF7a	$G \rightarrow T$	68	2.56
27,804nt	ORF7b	$C \rightarrow T$	85	3.2
28,830nt		C→A	85	3.2
28,833nt		$C \rightarrow T$	62	2.34
28,881nt		G→A	280	10.55
28,882nt		G→A	277	10.44
28,883nt	Nucleocapsid phosphoprotein	$G \rightarrow C$	276	10.4
28,932nt	I I I I	C→T	167	6.29
28,975nt		G→C	664	25.03
29,399nt		G→A	662	24.95
29,402nt		$G \rightarrow T$	73	2.75
29,645nt	ORF10	$G \rightarrow T$	169	6.37
29,779nt	3´UTR	$G \rightarrow T$	67	2.53
27,177Ht	JOIN	0 /1	01	4.33

06/01 -Table 10A - Spain 09/20/2020

medRxiv preprint (which was

Incidence he copyright holder for this preprint

our mtps://doi.org/10.1001/2021.02.04.21251111; this version posted February 6, 202

ot certified by peer review; is the author/funder, who has granted medRxiv is to a consider a CC. Provider with a constant of the consta o displayithe preprint in perpetuity. CN,DE,FR $CT \rightarrow TT$ 3,037nt 131/135 prevalent noneffective $GT \rightarrow TT$ ATGTAC (Methionine 5,572nt 11/135 unique Tyrosine) \rightarrow AT**TT**AC nsp3 (Isoleucine Tyrosine) $CT \rightarrow TT$ 5,784nt ACT (Threonine) $\rightarrow ATT$ 13/135 unique (Isoleucine) $CT \rightarrow TT$ DE,FR,ZA 6,286nt 89/135 noneffective $CT \rightarrow TT$ RNA-dependent RNA 14,408nt CCT (Proline) $\rightarrow CTT$ 132/135 prevalent polymerase (Leucine) $AG \rightarrow GG$ 20,268nt endoRNAse FR,RU,US,ZA 26/135 noneffective 2´-O-ribose $GT \rightarrow CT$ 21,255nt 84/135 DE,FR methyltransferase noneffective $CT \rightarrow TT$ 22,227nt 89/135 DE,FR,ZA noneffective $TA \rightarrow CA$ 22,297nt 11/135 RU noneffective $GA \to TA$ Spike glycoprotein 25,049nt GAT (Aspartic Acid) → TAT 18/135 DE (Tyrosine) $GT \rightarrow TT$ 25,062nt GGT (Glycine) $\rightarrow GTT$ 18/135 unique (Valine) $CA \rightarrow GA$ 26,801nt DE,FR,ZA 89/135 Membrane glycoprotein noneffective $CC \rightarrow TC$ 27,944nt FR 56/135 noneffective ORF8 protein $CA \rightarrow TA$ 27,982nt CCA (Proline) $\rightarrow CTA$ 13/135 unique (Leucine) $CG \rightarrow TG$ 28,657nt 19/135 unique noneffective $GGG \rightarrow AAC$ 28,881nt Nucleocapsid AGGGA (Arginine Glycine) 14/135 prevalent phosphoprotein → AAACGA (Lysine Arginine) $CT \rightarrow TT$ 28,932nt GCT (Alanine) $\rightarrow GTT$ 89/135 unique (Valine) $GT \rightarrow TT$ ORF10 protein 89/135 DE,FR 29,645nt noneffective

	Table 10B - S	Spain					
	Position	Location	Mutation	Total Count	Percentage		
dRxiv p	repriatibili: htt	os://doi.org/10.1101/2021.52/07.21251111; this version po	sted February 6	2024,699he co	pvria1944701der	for this prepr	
(which	was3nontcert	fied by peer review) is the author/funder, who has grante it is made available under a CC-BY-NC-ND 4.	d meɗR x íl√a lice	ense tbl@isplay	the preprint in	n perpetuity.	
		It is made available under a CC-BY-NC-ND 4.		cense ₈₅₈			
	1,059nt	nsp2	$C \rightarrow T$	122	3.56		
	1,987nt	115/12	A→G	75	2.19		
	3,037nt		$C \rightarrow T$	2,717	79.26		
	5,170nt	nsp3	$C \rightarrow T$	141	4.11		
	6,286nt	nsp3	$C \rightarrow T$	861	25.12		
	6,294nt		$T \rightarrow C$	82	2.39		
	8,782nt	nsp4	$C \rightarrow T$	601	17.53		
	9,477nt	nsp4	$T \rightarrow A$	379	11.06		
	11,083nt	nsp6	$G \rightarrow T$	166	4.84		
	11,132nt	nspo	$G \rightarrow T$	137	4		
	13,006nt	nsp9	$T \rightarrow C$	77	2.25		
	14,408nt	DNA demandant DNA malymoreae	$C \rightarrow T$	2,708	79		
	14,805nt	RNA-dependent RNA polymerase	$C \rightarrow T$	408	11.9		
	20,268nt	endoRNAse	A→G	1,223	35.68		
	21,255nt	2'-O-ribose methyltransferase	G→C	780	22.75		
	22,227nt		$C \rightarrow T$	843	24.59		
	23,403nt	Spike glycoprotein	A→G	2,731	79.67		
	25,049nt		$G \rightarrow T$	71	2.07		
	25,563nt		$G \rightarrow T$	147	4.29		
	25,688nt		$C \rightarrow T$	78	2.28		
	25,979nt	ORF3a	$G \rightarrow T$	371	10.82		
	26,088nt		$C \rightarrow T$	215	6.27		
	26,144nt		$G \rightarrow T$	100	2.92		
	26,801nt	Membrane glycoprotein	C→G	855	24.94		
	27,944nt		$C \rightarrow T$	456	13.3		
	28,144nt	ORF8	T→C	599	17.47		
	28,657nt		C→T	441	12.86		
	28,863nt		C→T	378	11.03		
	28,881nt		G→A	398	11.61		
	28,882nt	Nucleocapsid phosphoprotein	G→A	396	11.55		
	28,883nt		G→C	395	11.52		
	28,932nt		$C \rightarrow T$	850	24.8		
	29,645nt	ORF10	$G \rightarrow T$	840	24.5		
	29,734nt		G→C	302	8.81		
	29,870nt	3´UTR	C→A	107	3.12		

Table 11A -	Germany		DE-I 02 - 03/23 2020*	DE-II 02 - 06/17/2020	DE-III 06/24 - 08/28/2020	DE-IV 09/10 - 10/13/2020	
Position	Location	Mutation	Count	Count	Count	Count	Incidence
241nt	5 UTR	$CG \rightarrow TG$ noneffective	4/62	112/138	17/17	70/70	prevalent
445nt	nsp1	$TT \rightarrow CT$ TTG (Leucine) \rightarrow GTCTTG (Valine Leucine)	0/62	0/138	1/17	17/70	CN,FR
1,059nt		$CC \rightarrow TC$ ACC (Threonine) $\rightarrow ATC$ (Isoleucine)	21/62	27/138	0/17	2/70	prevalent
1,440nt	mom2	$GC \to AC$ $GGC (Glycine) \to GAC (Aspartic Acid)$	15/62	18/138	0/17	0/70	US
1,513nt	nsp2	$CC \rightarrow TC$ noneffective	0/62	0/138	0/17	13/70	unique
2,891nt		GC \rightarrow AC GCA (Alanine) \rightarrow ACA (Threonine)	15/62	18/138	0/17	0/70	US
3,037nt		$CT \rightarrow TT$	41/62	114/138	17/17	70/70	prevalent
2.602		noneffective $CA \rightarrow TA$	0/62	0/120	5/17	6/70	1
3,602nt		$\frac{\text{CAC (Histidine)} \rightarrow \text{TAC (Tyrosine)}}{\text{CA} \rightarrow \text{TA}}$	0/62	0/138	5/17	6/70	unique
4,543nt	nsp3	CA → 1A noneffective	0/62	0/138	5/17	2/70	ES,FR,US
6,286nt		$\begin{array}{c} \text{CT} \rightarrow \text{TT} \\ \text{noneffective} \end{array}$	0/62	0/138	1/17	17/70	ES,FR,ZA
6,941nt		$CT \rightarrow TT$ noneffective	0/62	0/138	5/17	6/70	unique
14,408nt		$ \begin{array}{c} \operatorname{CT} \to \operatorname{TT} \\ \operatorname{CCT} (\operatorname{Proline}) \to \operatorname{CTT} (\operatorname{Leucine}) \end{array} $	39/62	114/138	17/17	70/70	prevalent
15,324nt	RNA-dependent RNA polymerase	$CA \rightarrow TA$ noneffective	1/62	1/138	5/17	6/70	BR,CN,FR, IN
16,075nt		$GA \rightarrow TA$ $GAT (Aspartic Acid) \rightarrow TAT (Tyrosine)$	0/62	0/138	0/17	11/70	FR
19,839nt	endoRNAse	TA → CA noneffective	0/62	0/138	2/17	11/70	CN,ES,FR, IN,US
21,255nt	2´-O-ribose methyltransferase	$ \begin{array}{c} \text{Indicetve} \\ \text{GT} \to \text{CT} \\ \text{noneffective} \end{array} $	0/62	0/138	1/17	17/70	ES,FR
21,855nt		$CT \rightarrow TT$ $TCT (Serine) \rightarrow TTT (Phenylalanine)$	0/62	0/138	5/17	6/70	ZA
22,227nt		$CT \rightarrow TT$ noneffective		0/138	1/17	18/70	ES,FR,ZA
22,346nt	Spike glycoprotein	$GC \rightarrow TC$ $GCT (Alanine) \rightarrow TCT (Serine)$	0/62	0/138	0/17	13/70	unique
22,377nt		$ \begin{array}{c} \text{CT} \to \text{TT} \\ \text{CCT (Proline)} \to \text{CTT (Leucine)} \end{array} $		0/138	0/17	13/70	unique
23,403nt		$AT \rightarrow GT$ GAT (Aspartic Acid) $\rightarrow GGT$ (Glycine)	1/62	112/138	17/17	70/70	prevalent
25,505nt		$AA \rightarrow GA$ $CAA \text{ (Glutamine)} \rightarrow CGA \text{ (Arginine)}$	0/62	0/138	5/17	6/70	unique
25,563nt	ORF3a protein	$CAGAGC$ (Glutamine Serine) $\rightarrow CATAGC$ (Histidine Serine)		27/138	2/17	5/70	prevalent
25,906nt		$GG \rightarrow CG$ $GGT (Glycine) \rightarrow CGT (Arginine)$	0/62	0/138	5/17	6/70	unique
26,801nt	Membrane glycoprotein	$\begin{array}{c} CA \rightarrow GA \\ \text{noneffective} \end{array}$	1/62	0/138	1/17	17/70	ES,FR,ZA
27,046nt	Weinbrane grycoprotein	$CG \rightarrow TG$ ACG (Threonine) $\rightarrow ATG$ (Methionine)	1/62	16/138	3/17	0/70	BR,RU
28,651nt		$ \begin{array}{c} CA \rightarrow TA \\ \text{noneffective} \end{array} $	0/62	0/138	5/17	6/70	FR,RU
28,706nt		$CA \rightarrow TA$ $CAC \text{ (Histidine)} \rightarrow TAC \text{ (Tyrosine)}$	0/62	0/138	0/17	11/70	unique
28,869nt	Nucleocapsid phosphoprotein	$C \Lambda \rightarrow T \Lambda$		0/138	5/17	6/70	unique
28,881nt		GGG → AAC AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)		35/138	9/17	38/70	prevalent
28,932nt		$CT \rightarrow TT$ $GCT (Alanine) \rightarrow GTT (Valine)$	0/62	0/138	1/17	17/70	FR
29,645nt	ORF10 protein	$\begin{array}{c} \text{GT} \rightarrow \text{TT} \\ \text{noneffective} \end{array}$	0/62	0/138	1/17	17/70	ES,FR
29,751nt	3 UTR	$ GA \rightarrow CA $ noneffective	0/62	0/138	0/17	11/70	unique

Table 11B - Germany 01/19/2020 - 01/20/2021 Total Position Location Mutation Percentage Count medRxiv preprint and interest https://doi.org/10.1101/2021.02.04.21251111; this version posted February 6 (which was 204 to the by peer review) is the titil and review who has granted medRxiv a lice 202145 The capyright Rolder for this preprint er review) is the diffisor/funder, who has granted medicative a license teledisplay the preparint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license,790 86.64 241nt 86.64 313nt 2.57 $C \rightarrow T$ 53 ORF1ab polyprotein → leader protein 445nt $T \rightarrow C$ 159 7.7 1,059nt 399 19.31 $C{\rightarrow}T$ nsp2 1,440nt $G \rightarrow A$ 76 3.68 2,891nt 76 $G \rightarrow A$ 3.68 3,037nt $C \rightarrow T$ 1,796 86.93 2.57 3.73 53 77 3,373nt $C \rightarrow A$ 3,602nt $C \rightarrow T$ nsp3 4,543nt $C \rightarrow T$ 2.03 42 6,286nt $C \rightarrow T$ 155 7.5 6,406nt $C \rightarrow T$ 57 2.76 79 3.82 6,941nt $C \rightarrow T$ $C \rightarrow T$ 6.2 8,782nt 128 nsp4 11,083nt nsp6 $G \rightarrow T$ 91 4.4 86.25 2.37 $C \rightarrow T$ $C \rightarrow T$ 14,408nt 1,782 14,805nt RNA-dependent RNA polymerase 49 15,324nt $C \rightarrow T$ 138 6.68 $C \rightarrow T$ 55 18,877nt 2.66 3'-to-5' exonuclease 18,972nt G→A 58 2.81 19,839nt $T \rightarrow C$ 52 2.52 endoRNAse 20,268nt A→G 78 3.78 21,255nt 2'-O-ribose methyltransferase G→C 162 7.84 21,614nt $C \rightarrow T$ 45 2.18 21,855nt $C \rightarrow T$ 3.68 76 22,227nt $C \rightarrow T$ Spike glycoprotein 166 8.03 22,468nt $G \rightarrow T$ 116 5.61 23,403nt 87.12 $A \rightarrow G$ 1.800 25,505nt A→G 74 3.58 53 2.57 25,550nt $T \rightarrow A$ 25,563nt $G \rightarrow T$ 492 23.81 25,906nt ORF3a $G \rightarrow C$ 74 3.58 25,922nt $G \rightarrow T$ 50 2.42 25,996nt $G \rightarrow T$ 75 3.63 26,144nt $G \rightarrow T$ 44 2.13 26,530nt 55 2.66 A→G 26,735nt $C \rightarrow T$ 43 2.08 Membrane glycoprotein 145 7.02 26,801nt $C \rightarrow G$ 27,046nt $C \rightarrow T$ 3.29 68 27,944nt $C \rightarrow T$ 89 4.31 ORF8 28,144nt $T \rightarrow C$ 131 6.34 28,651nt $C \rightarrow T$ 74 3.58 28,854nt $C \rightarrow T$ 59 2.86 28,869nt $C \rightarrow T$ 75 3.63 28,878nt 124 $G \rightarrow A$ 6 Nucleocapsid phosphoprotein 28,881nt $G \rightarrow A$ 589 28.51 28,882nt 585 28.32 $G \rightarrow A$

ORF10

 $G \rightarrow C$

 $C{\rightarrow}T$

 $G \rightarrow T$

585

162

161

28.32

7.84 7.79

28,883nt

28,932nt

29,645nt

Table 12A		CN-I 12/23/2019 - 03/18/ 2020*	CN-II 03/20 - 07/22/2020	to for this over	
Position	Location by poor	review) is the author/function the has granted modPy	iv a license to d	color the broom	Incidence
241nt	5'UTR	o.1101/2021.02.04.21251111. this version posted Feb review) is the author/fulled who has granted medRx is made available under a CC-BY-NC-ND 4.0 International noneffective	ional lipense .	23/33	prevalent
3,037nt	nsp3	$CT \rightarrow TT$ noneffective	2/99	23/33	prevalent
8,782nt	nsp4	$CC \rightarrow TC$ noneffective	29/99	0/33	DE,ES,IN, US
14,408nt	RNA-dependent RNA polymerase	$CT \to TT$ $CCT \text{ (Proline)} \to CTT \text{ (Leucine)}$	2/99	19/33	prevalent
23,403nt	Spike glycoprotein	$AT \rightarrow GT$ $GAT \text{ (Aspartic Acid)} \rightarrow GGT \text{ (Glycine)}$	2/99	22/33	prevalent
28,144nt	ORF8 protein	$TA \rightarrow CA$ $TTA \text{ (Leucine)} \rightarrow TCA \text{ (Serine)}$	29/99	0/33	DE,ES,IN, US
28,881nt	Nucleocapsid phosphoprotein	GGG → AAC AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)	2/99	11/33	prevalent

Table 12B - China 01/19/2020 - 01/20/2021 Total Position Location Mutation Percentage Count 2.16 2,392nt $T \rightarrow C$ 13 3,037nt $C \rightarrow T$ 65 10.78 6,354nt $C \rightarrow T$ 14 2.32 nsp3 2.32 2.49 7,075nt T→C 14 $T \rightarrow G$ 8,022nt 15 8,782nt $C \rightarrow T$ 191 31.67 nsp4 10,747nt 3C-like proteinase $C \rightarrow T$ 2.32 14 11,083nt $G \rightarrow T$ 40 6.63 nsp6 11,794nt 2.32 A→G 14 9.12 14,408nt $C \rightarrow T$ 55 15,324nt $C \rightarrow T$ 13 2.16 2.32 $C \rightarrow T$ 15,342nt RNA-dependent RNA polymerase 14 15,360nt 2.32 $C \rightarrow T$ 14 2.32 15,666nt $G \rightarrow A$ 14 2.32 $C \rightarrow T$ $C \rightarrow T$ 16,733nt 14 Helicase 17,373nt 26 18,060nt 3'-to-5' exonuclease $C \rightarrow T$ 16 2.65 21,707nt $C \rightarrow T$ 24 3.98 21,727nt $C \rightarrow T$ 14 2.32 spike glycoprotein 2.65 22,020nt $T \rightarrow C$ 16 23,403nt A→G 67 11.11 25,416nt $C \rightarrow T$ 14 2.32 ORF3a 26,144nt $G{\rightarrow}T$ 39 6.47 27,213nt $C \rightarrow T$ 2.49 ORF6 15 $T \rightarrow C$ 28,144nt 212 35.16 ORF8 $T \rightarrow C$ $C \rightarrow T$ 2.16 2.32 28,688nt 13 28,854nt 14 28,881nt G→A 33 5.47 Nucleocapsid phosphoprotein 28,882nt $G \rightarrow A$ 31 5.14 28,883nt $G \rightarrow C$ 31 5.14 29,095nt $C \rightarrow T$ 31 5.14 29,742nt $G \rightarrow T$ 19 3.15

 $C \rightarrow T$

14

2.32

3´UTR

29,835nt

Country	Total number mutations	Novel Unique mutations	Novel Shared mutations	Sum novel mutations	Prevalent mutations	C to T transitions [in % of mutants]	RNA replication	Spike glycoprotein	Nucleocapsid phosphoprotein	Covid-19 cases	Covid-19 deaths
United Kingdom	medRxiv pre (waich w	print doi: http /as not certi	s://doi.org/10 fied bys peer It	0.1101/2021. review) is the lis made ava	02.04.21251 e author/fundilable under	111; this vers der, who has a CC-BY-NC-	ion posted Fe grante® medF ND 4.0 Intern	bruary 6, 2021 xxiv a license to ational license	The copyright hole display the prepri	der for this pr nt3ç⊽pe,ppetui	eprint 104,371 (2.77%)
South Africa	28	9	12	21 (75%)	7	46.4	4	7	3	1,443,939	43,633 (3.02%)
USA	39	17	13	30 (76.9%)	7	59	13	3	7	26,514,275	447,490 (1.69%)
India	23	9	9	18 (78.3%)	5	69.6	6	4	2	10,740,309	154,202 (1.44%)
Brazil	9	2	2	4 (44.4%)	5	44.4	1	2	2	9,119,477	222,775 (2.44%)
Russia	10	3	1	4 (40%)	6	50	2	1	1	3,832,080	72,697 (1.90%)
France	27	0	20	20 (74.1%)	7	40.7	7	2	5	3,153,487	75,620 (2.40%)
Spain	20	6	10	16 (80%)	4	50	3	4	3	2,830,478	58,319 (2.06%)
Germany	33	11	15	26 (78.8%)	7	51.5	5	5	5	2,209,057	57,150 (2.59%)
People's Republic of China	7	0	2	2 (28.6%)	5	57.1	1	1	1	89,430	4,636 (5.18%)

Table 13 – A Survey Covid-19 numbers – January 30, 2021